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ABSTRACT 
 
The ABC transporter superfamily is one of the largest and abundant families of 
proteins.  It is a large group of proteins that transport a range of substances in cell 
systems. The ABC transporter P-glycoprotein (ABCB1, P-gp), a polyspecific 
protein has demonstrated its function as a transporter of hydrophobic drugs as 
well as transporting lipids, steroids and metabolic products. As well as this, 
previous studies have shown that P-gp is over expressed in cancerous tissues and 
plays a role in multidrug resistance. In this study,     in-silico methods were used 
to dock a data set of compounds to P-glycoprotein structures available in the 
Protein data bank. Binding sites were defined using co-crystallised ligand 
structures of P-gp and docking energies were calculated using MOE. Statistical 
models were built to gain a better understanding of how compounds may interact 
with P-gp. The protein was able to bind to structurally different compounds and 
results indicate that LogP is the most important factor for drug binding to P-
glycoprotein. 
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1 Introduction 
1.1 Transporters 
In every living cell, the transport of molecules is an important part of its survival. 
For molecules to enter, leave or cross cell membranes they usually require a 
protein to aid their movement. It is reported that the human genome has nearly 
900 transporter genes (Anderle, et al, 2004) that encode proteins which are 
mainly responsible for transporting molecules, nutrients and drugs throughout 
the body. From this group, it is reported that approximately 350 are genes that 
encode intracellular transporters. These transporters can be separated into three 
classes relating to their binding or carrier potential; ATP powered pumps, 
channel transporters and translocators (Lodish, et al., 2000). ATP pumps are 
transporters that require energy from ATP hydrolysis to be able to transfer 
various molecules across a membrane against the concentration gradient.  ATP is 
hydrolysed to ADP and Pi, which release energy enabling transport of the 
molecule across the membrane. Examples of ATP powered pumps include ATP-
binding cassette transporter, Na+/K+-ATPase and Hydrogen potassium ATPase. 
Channel transporters create a passage through the membrane which they wish to 
transport molecules through. They are regularly involved in the transport of 
water and ions such as sodium and chloride which require transport across 
membranes by facilitated transport. 
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1.1 ABC Transporters 
The ABC transport superfamily is one of the largest and abundant families of 
proteins.  It is a large group of proteins that transport a range of substances that 
include amino acids, drugs and lipids as well as several others (Sharom, 2008).  
The ABC proteins can be located in several organ membranes in humans, and in 
prokaryotes they are found in the cytoplasmic membrane of bacteria (Sharom, 
2008).  
Part of their structure includes an ATP-binding domain that utilises ATP 
hydrolysis to transport compounds across cell membranes.  A typical ABC 
transporter has four core domains; two membrane-associated domains and two 
ATP-binding domains (Higgins, 2001). The trans-membrane domains are 
situated across the membrane and function as the route for molecules to cross the 
membrane. The ATP-binding domains are located in the cytoplasm of the cell 
and are consequently hydrophilic in nature (Dean, 2002).  
 
Figure 1. ABC transporter organisation.  Domains of ABC transporters can be expressed by different 
combinations. A) encoded as four individual polypeptides B) combined ATP-binding domain C) combined 
membrane-associated domains D) membrane-associated domain fused to ATP-binding domain E) 
membrane-associated domain fused to ATP-binding domain F) All domains fused into one single 
polypeptide (Higgins, 2001)  
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 ABC transporter proteins bind ATP and use the energy derived from this to 
transfer molecules across cell membranes. In eukaryotic cells, ABC transporters 
usually direct molecules from the cytoplasm to the outside of the cell (Dean, 
2002) with the main function of transporting xenobiotic compounds out of the 
cell for transport to other areas of the body or for excretion. On the other hand, 
ABC transporters in prokaryotic cells can be either an importer or exporter of 
compounds. Bacterial importers are important for the cell survival and typically 
important substrates such as iron, inorganic ions as well as peptides and amino 
acids. Substances requiring removal from prokaryotic cells include cell wall 
components such as liposaccharides and toxins involved in pathogens e.g. 
haemolysin (Davidson et al, 2008). ABC proteins also play a role in the 
translation of mRNA and are involved in repairing DNA. 
The ABC trans-membrane protein family is a large group and 48 ABC 
transporter genes have been recognised in the human genome (Ambudkar, et al., 
2003).  ABC genes are classified into subfamilies which are further divided into 
subgroups (Dean, 2002). The best studied groups include ABCB1 also known as 
MDR1 due to its ability to produce multiple drug resistance in cancer cells. The 
sulphonylurea receptor (SUR) subfamily is involved in regulating insulin 
secretion in β-cells of the pancreas (Dassa and Bouige, 2001).  Others include the 
ABCC subfamily which encodes the cystic fibrosis transmembrane conductance 
regulator (CFTR) protein that plays a part in exocrine secretions of chloride 
(Dean, 2002; Dassa and Bouige, 2001). Despite playing a functional role in cells, 
mutations in up to 14 mammalian ABC transporters have been associated with 
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disease states (Borst and Elferink, 2002). These proteins as well as ABCG2 and 
ABCB1 are reported to be overexpressed in malignant cells thus causing these 
cells to be resistant to drug therapy, hence the multidrug resistance terminology. 
1.1.2 Role of ABC Transporters in Multidrug Resistance 
During cancer treatment, tumour cells can become resistant to chemotherapy due 
to increased excretion of drugs out of tumour cells or target proteins (Dean, 
2002). Pathways such as these can lead to multidrug resistance thus contributing 
to the failure of chemotherapy in malignant diseases. Multidrug resistance is the 
term given to describe tumours developing resistance to two or more 
chemotherapeutic drugs. This is the net result of the over-expression of 
membrane transporters that actively remove toxic chemotherapeutic agents out of 
tumour cells (Sarkadi, et al., 2006). ABC transporters have been widely 
associated with resistance and the ABC genes ABCB1, ABCC1 and ABCG2 can 
be upregulated in cancerous cells. 
 For example, ABCG2 was first named as the Breast Cancer Resistant Protein 
(BCRP) when it was found in doxorubicin resistant cancer cells (Saito, et al., 
2010).  ABCG2 can be located in normal tissues and endothelial cells where it 
forms a barrier between blood supply and tissues. ABCG2 is also expressed in 
placental trophoblast cells, in the epithelium of small intestine and liver 
membrane as well as ducts and lobes of the breast (Saito, et al., 2010). The fact 
that there are high levels of expression of this protein in trophoblast cells 
suggests that BCRP is responsible for transporting compounds into blood supply 
and for removing toxic metabolites (Satio, et al., 2010). 
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The ABCC1 gene encodes for the multidrug resistance protein MRP1 (Dassa and 
Bouige, 2001). MRP1 is expressed in epithelial cells and in non-malignant cells 
it plays a role in protecting kidney tissues, bone marrow and the intestinal 
mucosa from xenobiotics as well as contributing to the removal of drugs from the 
cerebrospinal fluid (Schinkel and Jonker, 2012). Moreover, MRP1 confers drug 
resistance to a range of cancer drugs and transports conjugates of hydrophobic 
drugs as well as organic anions (Schinkel and Jonker, 2012).  
P-glycoprotein is the transporter encoded by the ABCB1 gene. It was one of the 
first ABC transporters to be associated with resistance (Leslie, et al., 2005) and 
led to the discovery of other genes in the ABC transporter family involved in 
multidrug resistance. P-glycoprotein is one of the most widely studied ABC 
transporters because it transports a wide range of substrates including anticancer 
drugs. P-glycoprotein is highly expressed in cancerous tissues and it is reported 
to be involved in cancers of the liver, colon and kidney tissues (Schinkel and 
Jonker, 2012). Due to its diverse substrate specificity, scientists have sought to 
gain a better understanding of how substrates bind to it, in order to develop 
potential inhibitors that may improve the efficacy of anticancer therapy. 
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1.2 P-glycoprotein 
P-glycoprotein (P-gp), a well studied glycoprotein was first discovered in 1976 
by surface labelling studies in drug resistant ovary cells (Juliano and Ling, 1976). 
Since then, it has demonstrated its function as a transporter of hydrophobic drugs 
as well as transporting lipids, steroids and metabolic products. Encoded by the 
ABCB1 gene, it is also known to play a role in transporting compounds across 
the blood brain barrier and is involved in the uptake of the cardiac glycoside 
Digoxin in the kidneys (de Lannoy and Silverman, 1992).  It is highly expressed 
in various cells of the body but is mainly presented in epithelial cells. In the 
blood brain barrier, P-gp protects the brain from toxic products and drugs that 
cross this threshold. P-gp substrates that are lipophilic can easily diffuse across 
endothelial cells and enter the brain. However a high proportion of P-gp 
surrounds this area of the brain preventing their accumulation and the role of     
P-gp is to distribute substrates back into blood circulation (Schinkel and Jonker, 
2012). Similarly in cells of the liver, P-gp is responsible for the excretion of 
drugs from hepatocytes into the bile thus reducing the bioavailability of drugs 
exerting their effects in these cells. Inclusive of these two areas, P-gp can also be 
found to be expressed in the intestines, placenta, kidneys and adrenal glands 
excreting harmful metabolic products (Dean, 2002).  
 
 
 
 
7 
 
 
1.2.1 Structure of P-glycoprotein 
As described previously, most ABC transporters consist of two trans-membrane 
domains and an ATP-binding domain that uses energy from ATP to transport 
products (Figure 1).  P-glycoprotein is known as a full transporter and contains 
six transmembrane domains with an ATP-binding domain separated by a flexible 
linker region (Ambudkar, et al., 2003). The structure of human p-glycoprotein 
was first elucidated by electron microscopy (Rosenberg, et al., 1997) and image 
analysis. P-gp was reported as having a central core with an opening to the 
extracellular side of the membrane but is closed towards the cytoplasm.   
In 2009, Aller et al reported a medium resolution (3.8-4.4Å) X-ray structure of               
P-glycoprotein that supported previous claims about the structure of P-gp and 
revealed tentative binding sites for drug compounds (Aller, et al., 2009). The 
study proposed the structure for mouse P-gp with 87% sequence identity to 
human p-glycoprotein (Figure 2). In addition to this, the structure of P-gp co-
crystallised with the cyclic peptide inhibitors cyclic-tris-(R)-valineselenazole 
(QZ59-RRR) and cyclic-tris-(S)-valineselenazole (QZ59-SSS) was also 
determined, suggesting particular amino acid residues that are involved in drug 
binding (Figure 2). 
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1.2.2 Binding sites of P-glycoprotein 
The X-ray crystal structures proposed by Aller did give some useful information 
regarding the amino acid residues involved in substrate binding to P-gp.  The 
crystal structure showed one molecule of QZ59-RRR bound to the middle site in 
the binding pocket (Figure 2B), and two molecules of QZ59-SSS bound at upper 
and lower sites which are overlapping the middle site (Figure 2C). This showed 
that P-gp can bind to two drug molecules at the same time and confirmed the 
diverse and polyspecific nature of P-glycoprotein (Gutmann, et al., 2009).  
 The binding pocket was said to include the transmembrane helices 1, 6, 7 and 12 
which mainly consisted of hydrophobic and aromatic residues. These included 
Phenylalanine (Phe) and Tyrosine (Tyr) residues in addition to the aromatic and 
aliphatic residues Serine, Threonine and Glutamine (Ser, Thr, Gln).  Despite 
these key attributes being made available, questions have been raised about the 
absence of ATP in the structure and the fact that the structures do not appear to 
undergo conformational changes upon drug binding (Gottesman, et al., 2009).  
Substrates of P-gp mainly interact with the protein by hydrophobic interactions, 
π-π stacking and Van der Waals forces. The P-gp X-ray crystal structure also 
shows this as the cyclic peptide inhibitors bind to P-gp through hydrophobic 
aromatic side residues (Aller, et al., 2009). Studies have also demonstrated that 
P-glycoprotein is a flexible molecule that can alter its confirmation in order for 
substrate entry. These findings led to a proposed induced-fit mechanism for drug 
binding to P-gp, in which the substrate enters the large binding pocket and both 
drug and protein modify their shape to generate more favourable contacts unique 
to that substrate (Alonso, et al., 2006).  
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This mechanism is supported by the X-ray structure of P-gp, where each of the 
ligands bound to P-gp interact with the protein at different or the same 
overlapping amino acid residues (Figure 3). 
 
 
 
 
 
 
 
 
1.3 In-Silico Methods 
Traditionally, drugs are usually discovered in biological assays and in time-
consuming   in vivo and in vitro testing. However, the use of computer modelling 
in drug discovery has rapidly been developed creating techniques and software 
that are able to analyse and predict information about biological, chemical and 
medical data. The term ‘In-Silico’ refers to the computational approach of drug 
discovery which is complementary to in vivo and in vitro experiments (Ekins, et 
al., 2007). In a widely expanding field, in-silico techniques have been used to 
create virtual models that enable scientists to make predictions about biological 
activity and provide advances in medicine.  
Figure 3. Venn diagram of amino acid residues involved in binding of cyclic peptide 
inhibitors and those predicted to be involved in Verapamil binding. (Aller, et al., 2009) 
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Various approaches can be considered an in-silico method, and one of the most 
well known is quantitative structure-activity relationships (QSAR). Since the 
1960s, QSAR has been used to describe the mathematical relationship between 
the structure of a molecule and biological activity (Van de Waterbeemd and 
Rose, 2003). It has now been further developed with branches of 2D and 3D 
QSAR methods based on the type of molecular descriptors involved. In contrast 
to QSAR is virtual screening, a knowledge based method that requires structural 
information about the target or the compound being developed (Klebe, 2006). A 
sample of small molecules highlighted as candidate ligands are ranked in order 
of affinity for the target and this way of generating lead compounds has become 
an essential part of the pharmaceutical industry. Other in-silico methods involve 
pharmacophore modelling that uses 3D structure representations to describe how 
candidate ligands may bind to a target (Ekins, et al., 2007). Target based methods 
involve docking compounds to a target site and the use of scoring functions to 
score the binding affinity of the ligand to the target. It has gained popularity in 
recent times and has been involved in the discovery of inhibitors of HIV-1 
integrase (Hayouka, et al., 2010). 
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1.4 Molecular Docking 
Molecular docking is a computational method used to estimate the binding 
energy of a ligand to a specific receptor (Huang, 2007). It is the process of 
building a model based on molecular properties of an individual compound or a 
library of compounds with a target structure usually a protein. In protein ligand 
docking, the docking program aims to find the preferred conformation of the 
ligand at a binding site of the target (Sousa., et al, 2006). The binding energy is 
then calculated for each conformation and is ranked and scored to give an 
estimation of the binding affinity between a compound and target. Docking has 
been successful in the discovery of novel ligands and inhibitors of enzymes. 
Docking has also been involved in producing inhibitors of aldose reductase 
(Iwata, 2001), carbonic anhydrase as well as HIV-1 integrase mentioned 
previously.  
At present, there is a wide range of docking software available in the market with 
different scoring functions. The program AUTODOCK is one of the most cited 
docking programs and uses the Lamarckian genetic algorithm as well as a 
traditional genetic algorithm (Sousa, et al., 2006). GOLD is another program that 
is popular in the field and enables flexibility of the protein hydrogen bonds as 
well as the ligand being tested. Unlike AUTODOCK, docking scores in GOLD 
are ranked using a force field scoring function that includes the contributions of 
hydrophobic interactions, Van der Waals forces and number of hydrogen bonds 
(Cummings, et al., 2005). FlexX is another software package that permits protein 
flexibility and scores the final position of molecules using the empirical Böhm’s 
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scoring function (Sousa, et al., 2006). In addition to these aforementioned 
programs, the Molecular Operating Environment (MOE) is a suite of applications 
that can be used for medicinal chemistry purposes. It includes a docking tool that 
searches for complimentary binding poses between a ligand and a rigid receptor 
which can be used to determine interactions between candidate ligands and 
targets. 
1.4.1 Scoring Functions 
Scoring functions are used to calculate the binding energy of poses generated 
after docking placement. A very accurate scoring function is desired to be able to 
successfully predict binding affinity, however due to the complexity and high 
computational cost involved, scoring functions make assumptions about 
molecular interactions based on experimental data from independent reactions 
(Lipkowitz and Boyd, 2002).  In all scoring functions, a lower score indicates a 
more favourable pose while higher scores suggest that binding is less likely. 
Scoring functions are based on different calculation methods and can be divided 
into three categories: knowledge-based, force field and empirical based methods. 
 Knowledge-based functions use data from statistical analysis of structural 
complexes in the protein data bank, to estimate interatomic reactions occurring 
frequently between a ligand and the protein in specified intervals (Schulz-Gasch 
and Stahl, 2004). Typical examples of knowledge based scoring functions 
include Muegges’s potential of Mean Force (PMF), DrugScore and the SMoG 
score (Sousa, Fernandes and Ramos, 2006).  
13 
 
GoldScore, Assisted Model Building and Energy Refinement (AMBER) and the 
Optimised Potentials for Liquid Simulations function (OPLS), are examples of 
force-field scoring functions. Force-field scores are calculated by measuring 
electrostatic and Van der Waals interactions (Schulz-Gasch and Stahl, 2004) but 
is limited by the exclusion of solvation and entropic properties (Sousa, et al., 
2006). In contrast to these two scoring functions, empirical scores estimate free 
binding energy based on a sum of localised independent reactions (Lipkowitz 
and Boyd, 2002). In most cases, the constants in empirical formulas are derived 
from binding energies calculated in experiments of receptor-ligand complexes 
(Sousa, et al., 2006).  An example of an empirical scoring function is the London 
dG scoring utilised in MOE (Figure 4).  
 
Figure 4. London dG Scoring Function (Corbeil et al, 2012) 
The formula above calculates binding energy where Eflex represents the energy 
due to loss of flexibility of the ligand, ƒhb and Сhb are measurements of hydrogen 
bonds while СM and ƒM measure energies related to metal ligation.   
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1.5 Data Mining 
Data mining is the process of extracting information and establishing 
relationships from large sets of data. Methods involve computer-based statistics, 
pattern recognition and database technology (Hand, et al., 2001).  Data mining 
methods can be classified into two categories: predictive and descriptive data 
mining (Kantardzic, 2011). Descriptive data mining tools aim to produce new 
information about a dataset and to establish patterns and relationships from a 
large data set. In contrast, predictive methods are for building models regarding 
the information available in the database which can then be used to make 
predictions or classify data (Kantardzic, 2011).  
Classification and regression trees (CART) are predictive systems that can be 
used to classify data into pre-defined classes. Decision trees are built which split 
data into categories in response to a dependent variable. Classification trees are 
developed if the dependent variable is categorical (e.g. substrate/non-substrate) 
and regression trees are formed when continuous data is available (Deconinck, et 
al., 2005). Interaction trees are similar but the user can manually select a variable 
as the independent variable and then allow the software to grow the tree 
automatically. Support Vector Machine (SVM) is a machine learning method 
that uses a mathematical algorithm to classify data. It constructs a hyperplane in 
a high dimensional space which separate sets of linear data by the maximum 
margin (Lipkowitz, Cundari, 2007). In the case of non-linear data, SVM 
constructs a higher dimensional feature space, using Kernel functions such as 
Gaussians, polynomial and RBF kernels (Wang, 2005).  
 
15 
 
1.6 Research objectives 
P-glycoprotein is a poly-specific protein and is able to recognise structurally 
diverse substrates. In this study, we aim to develop a better understanding of how 
compounds interact with P-gp. It is our aim to build a model using statistical 
methods to describe the common features of compounds that bind to                  
P-glycoprotein. In addition to this, there are currently three X-ray structures of  
P-gp available in the protein data bank (3G5U, 3G60, 3G61). In these structures, 
there are at least two binding sites that have been suggested. It is our aim to 
optimise the molecular docking strategy to identify substrates of P-gp and 
suggest the most favourable binding site. By doing this, we can establish the type 
of interactions that occur between P-gp substrates in the drug binding pocket and 
provide information about the amino acid residues that are involved. 
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2  Methods 
2.1 Data Set 
Compounds used in the data set as part of this study, were selected from a 
previous research paper, Matsson et al, (2009) which had studied activity of ABC 
transporters. The compounds in the data set had been chosen as they represented 
a cross section of available and licensed oral drugs. The compounds in the data 
set are reported as inhibitors and non-inhibitors of P-gp based on the previous 
experimental results. Using this information, each compound was assigned a 
value of ‘1’ if in the literature it was a substrate or inhibitor and assigned a value 
of ‘0’ if it was a non-inhibitor.   
We then proceeded to gather the simplified molecular-input line-entry system 
code (SMILES) and the registration number (RN) for each compound into 
Microsoft Excel. This information was collected from online databases 
ChemSpider and Pubchem. These databases were used as they are available to 
access for free and provide reliable information about the structures and 
properties of millions of compounds. While searching for the SMILES code for 
Ivermectin, we noticed that it had two isomers which had not been included in 
the data extracted from the literature. As a result, we decided to use both isomers 
and include this in our data set (Ivermectin A & B). In total, 123 compounds 
were included in our data set (Table 1), with 54 classified as substrates and 69 
non-substrates.  From the 123 compounds, 98 compounds were separated 
randomly into a training set and 25 in the validation set. 
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Table 1. Substrates and Non-Substrate of P-glycoprotein. 0=non substrate,     
1=substrate 
Compound ABCB1P-gp Compound ABCB1-Pgp Compound ABCB1-Pgp 
Chlorprotixene 
Cyclosporine-A 
Diethylstilbestrol  
Dipyridamole 
Flupentixol 
GF120918 
Isradipine 
Ivermectin 
Loperamide 
Lopinavir 
MK571  
Quercetin 
Reserpine 
Ritonavir  
Saquinavir  
Silymarin  
Tamoxifen  
Terfenadine  
Thioridazine 
Benzbromarone 
Amiodarone 
Apigenin 
17β-estradiol  
Biochanin A 
Chlorpromazine 
Chrysin 
Ergocristine  
Felodipine  
Gefitinib  
Genistein 
Glibenclamide 
Imatinib mesylate 
Ketoconazole  
Kol 43 
Medroxyprogesterone 
Mifepristone 
Nicardipine 
Nitrendipine  
Simvastatin 
Tipranavir 
Verapamil 
 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
 
Diltiazem 
Taurolithocholic acid  
Haloperidol 
Maprotiline  
Noscapine 
Prednisone  
Procyclidine 
Propafenone 
Quinidine 
Quinine f 
Taurocholate 
Tetracycline 
Vinblastine 
Amodiaquine  
Fumitremorgin  
Hoechst 33342 
Mitoxantrone 
Naringenin 
Omeprazole 
Prazosin 
Progesterone 
Bromosulfalein 
Lansoprazole 
P-aminohippuric acid 
Rifampicin 
1-methyl-4-phenylpyridinium 
4-Methylumbelliferoneglucuronide 
Amantadine  
Amiloride 
Amitriptyline  
Antipyrine 
Atropine 
Budesonide 
Captopril 
Carbamazepine 
Carnitine 
Cefamandole 
Chloroquine 
Chlorzoxazone  
Cholic acid  
Cimetidine 
 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
Colchicine 
Dehydroisoandrosterone-3-sulfate 
Desipramine  
Digoxin 
Doxorubicin 
Erythromycin  
Estradiol-17β- 
Etoposide 
Fexofenadine  
Flucloxacillin 
Hydrochlorothiazide 
Hydrocortisone f 
Indinavir 
Indomethacin  
Mesalazine 
Methotrexate  
Metoprolol  
Nevirapine  
Nicotine 
Ofloxacin 
Phenobarbital  
Phenylethyl isothiocyanate 
Phenytoin  
Pravastatin 
Prednisolone  
Probenecid 
Propranolol 
Ranitidine  
Sotalol 
Sparfloxacin 
Sulfasalazine 
Sulfinpyrazone 
Sulindac 
Testosterone  
Tinidazole 
Trimethoprim  
Valproic acid  
Warfarin  
Vincristine 
Zidovudine 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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2.2 Calculation of Molecular Properties 
The SMILES codes collected from online databases was added to an Excel 
spreadsheet. From Excel, the chemical name and SMILES code of all 
compounds in the data set was copied and pasted into a notepad file. It was then 
saved as “.txt” file because this is the format that can be read by the software.  
This file was imported into Advanced Chemistry Development, Inc. ACD Labs/ 
Log D Suite Version 12.0 (ACD/Labs) software which is an application used to 
calculate molecular properties. Some of the compounds are in salt form, so 
before calculations the desalt function of the software was used to remove the 
ionic forms of some of the compounds and minimise their charges. Molecular 
properties were calculated for 123 compounds and examples of descriptors 
calculated include pKa, LogD, LogP and molar volume. The structure of each 
compound was saved by ACD Labs/ Log D (ACDlabs) in SDF file format. It was 
saved this way as this will allow the Molecular Operating Environment (MOE) 
software to read the structures formed in ACDlabs and produce a 3D version of 
the structures. 
2.3 Preparation of compounds for Docking 
Before docking could take place, the SDF file was imported into the software 
MOE. MOE is a suite of applications that can be used to manipulate and analyse 
a collection of compounds.  For docking to work efficiently, it is essential that 
each structure is in a form suitable for it to be docked to a ligand. As a result, the 
software’s ‘Wash’ application was used to clean the structures and neutralise the 
protonation state of each compound. This will neutralise all atoms and form the 
structure of the compound in its least charge-bearing state. The next step was to 
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lower the potential energy of the structures. This was completed using the 
“Energy minimize” function from the software. The compounds in the database 
were now ready to be computed and molecular descriptors were calculated. In 
total, MOE calculated 320 descriptors for the compounds in the dataset.  
2.4 Protein-Ligand Docking 
Docking of compounds in the dataset was carried out using the Dock application 
in MOE. The structure of the P-gp protein that the compounds in our dataset 
would be docked to was downloaded from the Protein Data Bank (PDB) online. 
The X-ray structure of mouse P-gp, 3G5U (QZ59-RRR bound) and 3G61 
(QZ59-RRR bound), were used for docking. The docking site for P-gp 3G5U 
was determined using residues that have been shown to interact with cyclic-
peptide inhibitors (Aller, et al., 2009). In total, 4 docking sites and their 
interacting residues were identified for P-gp 3G5U; Verapamil site, QZ59-RRR, 
QZ59-SSS upper and QZ59-SSS lower sites. The docking site of P-gp 3G61 was 
determined using the co-crystallised ligand QZ59-SSS already bound to the 
protein. The amino acid residues involved in each of the sites has been reported 
in Table 2. In the MOE software, the default Triangle Matcher was used as the 
placement method followed by forcefield refinement and London dG scoring 
was used for the docking runs. The top scoring conformation of each compound 
for each binding site was calculated as well as the root mean square deviation of 
each pose (RMSD). The maximum number of poses kept after the rescoring 
stage was 30 and duplicates were also removed 
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2.5 Statistical Analysis 
Results collected from docking scores and molecular descriptor calculations were 
analysed using data mining tools on Statistica 11.0 software. Data mining tools 
that were used for this study include Classification and Regression Tree (CART), 
Support Vector Machine and Interactive Tree (IT). CART is a statistical method 
that is used to partition data based on continuous dependent variables 
(regression) or categorical predictor variables (classification). In this study, 
CART was used to determine the importance of variables such as docking scores 
and molecular descriptors for classification of substrates and non-substrates.  
In all CART models that were developed, substrate/non-substrate property 
(ABCB1-Pgp) was the dependent variable and in each model other variables 
acted as independent variables. The dependent variable was categorical i.e. 1 
(substrate), 0 (nonsubstrate), therefore categorical analysis was performed.  
Interactive tree are similar to CART, however a specific independent variable 
e.g. docking scores at QZ59-SSS (lower) site was chosen manually as the first 
splitting variable and then the tree was allowed to grow further using statistically 
selected variables.  
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Table 2. Amino acid residues used for the definition of binding site 
Binding site Amino acid Residues P-gp model  
Verapamil  H60, A63, L64, S218, I302, L335, 
A338, F724, I864, G868, F938, T941, 
L971, V978, G980, A981 
3G5U 
QZ59-SSS(upper) M68, F332, I336, Y949, F974, V978, 
A981 
3G5U 
QZ59-SSS (lower) L300, Y303, F339, Q721, F724, L758, 
F833, F974, V978, A981, M982, 
G985, Q986, S989 
3G5U 
QZ59-RRR M68, Y303, F332, L335, I338, F339, 
Q721, F724, F728, Y949, F974, S975, 
V978 
3G5U 
QZ59-SSS M68, F332, I336, Y949, F974, V978, 
A981 
L300, Y303, F339, Q721, F724, L758, 
F833, F974, V978, A981, M982, 
G985, Q986, S989 
3G61 
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Average Score 
Average Score
-15.00
-10.00
-5.00
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Kcal/mol 
Average Score 
 
Non-substrate
Substrate
3 Results 
3.1 Docking results 
Docking energies for each compound was calculated by docking each compound 
to the three binding sites of 3G5U and the cyclic peptide binding site of 3G61. 
The lowest score for each compound was recorded and the average was 
calculated. The average of the lowest docking energies is shown in the graph 
below for all 123 compounds (Figure 5). The average docking energy for 
substrate and non-substrate is also shown (Figure 6). 
 Figure 5.  Average of the lowest docking scores 
 
Figure 6.  Average docking energy of substrate and non-substrates 
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Table 3. Docking energy of top three poses for all compounds 
The table below shows the average value of the top three docking energies 
calculated for all compounds at each binding site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Binding site Docking energy of top three 
scoring poses (kcal/mol) 
Average  
(kcal/mol) 
Verapamil – 3G5U 
 
-15.4 -12.97 -12.3 -13.6 
QZ59SSSupper – 3G5U 
 
-17.5 -15.3 -14.8 -15.9 
QZ59SSSlower – 3G5U -15.7 -15.7 -15.1 -15.5 
QZ59RRRlower – 3G5U -16.9 -15.6 -14.2 -15.6 
QZ59SSS – 3G61 
 
-17.6 -15.9 -15.7 -16.4 
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3.1.2 Docking Performance 
After obtaining docking scores for each compound, docking energies were 
evaluated to determine which compounds had greater affinity for the binding 
sites of P-gp.  The table on the following page shows the top ten compounds that 
had good docking performance at each binding site. 
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Table 4. Compounds with high docking performance 
 
 
 
 
 
 
Compound  
Verapamil 
Compound QZ59sss-upper Compound QZ59sss-lower Compound     QZ59rrr Compound      3G61 
   Score      Score       Score      Score     Score 
Ivermectin A -15.407999 Ivermectin A -17.49052 Ivermectin B -15.702105 Cyclosporine-A -16.93857 Cyclosporine-A -17.6087 
Bromosulfalein -12.974476 Digoxin -15.264123 Cyclosporine-A -15.671002 Rifampicin -15.607213 Rifampicin -15.8589 
Doxorubicin -12.270447 Rifampicin -14.776971 Ivermectin A -15.053252 Ivermectin A -14.21278 Bromosulfalein -15.7715 
Tetracycline -12.25106 Ivermectin B -14.182034 Digoxin -13.845214 Taurocholate -13.826485 Silymarin  -15.6766 
Silymarin  -12.211308 Cyclosporine 
A 
-13.913272 Erythromycin  -12.796752 Etoposide -12.774714 Etoposide -15.3638 
Mitoxantrone -12.069983 Silymarin  -12.740396 Rifampicin -12.707092 Ivermectin B -12.753691 Taurocholate -15.2546 
Methotrexate  -11.986519 Colchicine -12.727611 Doxorubicin -12.654102 Erythromycin  -12.736913 Doxorubicin -14.8735 
Tipranavir -11.627663 Methotrexate  -12.722812 Bromosulfalein -11.747195 Bromosulfalein -12.696462 Vincristine -14.4704 
Estradiol-17β-glucuronide  -11.490866 Vincristine -12.462447 Flupentixol -11.41256 Digoxin -12.67726 Reserpine -14.4181 
Budesonide -11.293019 Bromosulfalein -12.310234 Vinblastine -11.387159 Silymarin  -12.592422 Digoxin -14.2525 
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3.1.3 Docked compounds 
Docking runs were performed for each binding site and docking energies 
calculated. Below are images of example compounds docked to different binding 
sites of 3G5U and 3G61. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Ivermectin A (blue) docked to 
QZ59-SSS (upper) binding site of 3G5U 
 
 Figure 8. Ivermectin A (blue) docked to 
QZ59-SSS(lower) binding site of 3G5U. 
Figure 10. Chlorprotixene (blue) docked to     
binding site of 3G61 
 
 Figure 7. 17-β-estradiol (blue) docked to 
Verapamil  binding site of 3G5U. 
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3.2 Statistical Models 
3.2.1 Classification Trees (CART) 
Classification trees were developed to make predictions about the classification 
of substrates and non-substrates.  In all classification trees developed, 
substrate/non-substrate property (ABCB1-Pgp) was the dependent variable. 
Several models were developed because in each model particular variables were 
selected as the independent variable e.g. Docking scores. In order to control the 
splitting of the tree, the minimum number of cases was 49 and maximum cases 
were 1000.  
 
CART 2 – Using all docking scores for each binding site as independent 
variables  
 
 
 
 
 
 
 
 
 
 
 
 
 
          Figure 11   Parameters: 0 (Non-substrate), 1 (Substrate)  
          S/QZ59rrr – Docking score at the QZ59rrr binding site (3G5U) 
          S/QZ59upper – Docking score at the QZ59upper binding site (3G5U) 
          S/QZ59lower – Docking score at QZ59lower binding site (3G5U) 
 
Tree 1 graph for ABCB1P-gp
Num. of non-terminal nodes: 3,  Num. of terminal nodes: 4
ID=1 N=98
0
ID=2 N=68
1
ID=5 N=49
1
ID=4 N=19
0
ID=6 N=36
1
ID=7 N=13
0
ID=3 N=30
0
S/QZ59rrr
<= -9.264243 > -9.264243
S/QZ59upper
<= -11.383177 > -11.383177
S/QZ59lower
<= -9.039293 > -9.039293
0
1
28 
 
CART  3 – Using Docking score at 3G61-QZ59SSS site and RMSD as independent 
variables 
 
 
 
 
 
 
 
 
 
 
 
 
CART 4 – Docking scores of all binding sites and molecular descriptors 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12   
Parameters: 0 (Non-substrate) , 1 (Substrate) , S/3G61-QZ59RR – Docking score at the QZ59rrr site (3G61) 
Rmsd_refine – The root mean square deviation of the pose 
Tree 1 graph for ABCB1P-gp
Num. of non-terminal nodes: 7,  Num. of terminal nodes: 8
ID=1 N=94
0
ID=2 N=36
0
ID=3 N=58
1
ID=7 N=48
1
ID=8 N=33
1
ID=10 N=32
1
ID=9 N=15
0
ID=4 N=33
0
ID=5 N=3
1
ID=6 N=10
0
ID=12 N=31
1
ID=13 N=1
0
ID=11 N=1
0
ID=14 N=8
0
ID=15 N=7
1
LogP
<= 2.670000 > 2.670000
SMR_VSA2
<= 54.606751 > 54.606751
vsurf_IW4
<= 1.187956 > 1.187956
GCUT_PEOE_1
<= -0.380854 > -0.380854
AM1_IP
<= 10.280640 > 10.280640
VSA
<= 765.587555 > 765.587555
SMR_VSA7
<= 119.552365 > 119.552365
0
1
Figure 13 
Parameters: 
LogP - Log of the octanol/water partition coefficient, 
SMR_VSA2 – Sum of van der Waals surface area (in Å2) such that Molar Refractivity is in (0.26,0.35), 
V surf_IW4 – Hydrophillic integy moment 
GCUT_PEOE_1 - PEOE partial charge GCUT (1/3) 
AM1_IP - The ionization potential (kcal/mol) calculated using the AM1 Hamiltonian [MOPAC] 
SMR_VSA7 - Sum of van der Waals surface area (in Å2) such that Molar Refractivity is > 0.56 
VSA - Approximation to the sum of VDW surface areas 
Tree 1 graph for ABCB1P-gp
Num. of non-terminal nodes: 3,  Num. of terminal nodes: 4
ID=1 N=98
0
ID=2 N=84
1
ID=4 N=70
1
ID=6 N=41
1
ID=7 N=29
0
ID=5 N=14
0
ID=3 N=14
0
S/3G61-QZ59SSS
<= -8.805785 > -8.805785
rmsd_refine/3G61-QZ59SSS
<= 2.181203 > 2.181203
S/3G61-QZ59SSS
<= -11.092090 > -11.092090
0
1
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3.2.2 Interactive Trees 
The aim of using interactive trees was to manually select one independent 
variable as the first splitting criteria and then allow the software to statistically 
select other important variables to grow the tree. In Figure 10, the first splitting 
criteria was the Docking score of all compounds at QZ59-RRR binding site 
(3G5U) and in Figure 11, Docking score at the QZ59lower binding site (3G5U) 
was the first splitting variable. Interactive tree models developed are shown 
below. 
IT 1 – Docking score S/QZ59RRR dependent variable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tree graph f or ABCB1P-gp
Num. of  non-terminal nodes: 3,  Num. of  terminal nodes: 4
Model: C&RT
ID=1 N=98
0
ID=10 N=68
1
ID=12 N=32
0
ID=14 N=23
0
ID=15 N=9
1
ID=13 N=36
1
ID=11 N=30
0
S/QZ59rrr
<= -9.260000 > -9.260000
LogD(10)
<= 2.370000 > 2.370000
LogD(2)
<= 2.945000 > 2.945000
0
1
Figure 14 
Parameters: S/QZ59rrr - Docking score at the QZ59-RRR binding site (3G5U) and is the 
Dependent variable 
LogD – Log of the distribution coefficient  
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IT 2 – Docking score S/QZ59lower dependent variable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tree graph f or ABCB1P-gp
Num. of  non-terminal nodes: 4,  Num. of  terminal nodes: 5
Model: C&RT
ID=1 N=98
0
ID=10 N=61
1
ID=12 N=27
0
ID=11 N=37
0
ID=14 N=20
0
ID=15 N=7
1
ID=13 N=34
1
ID=16 N=27
0
ID=17 N=10
1
S/QZ59lower
<= -9.040000 > -9.040000
LogD(10)
<= 2.230000 > 2.230000
LogD(2)
<= 2.875000 > 2.875000
Q_VSA_HYD
<= 277.885435 > 277.885435
0
1
Figure 15 
Parameters: S/QZ59rrr - Docking score at the QZ59-SSS (lower) binding site (3G5U) and is the 
Dependent variable 
LogD – Log of the distribution coefficient  
Q_VSA_HYD - Total hydrophobic van der Waals surface area. 
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3.2.3 Support Vector Machine Models 
Further classification models were developed using Support Vector Machine. 
SVM Classification type 1 was used for all SVM calculations and Radial Basis 
Function (RBF) was selected as the kernel type. The independent variables were 
manually selected from the CART and Interactive trees developed.  
Table 5. SVM Models 
Model 
No. 
Dependent  Independent SVM Type Kernel Type               Accuracy 
Training Test Overall 
SVM 
1. 
ABCB1-Pgp S/3G61-
QZ59RR 
S/QZ59upper 
S/QZ59RRR 
 
Classificatio
n type 1 
Capacity=7.
00 
Radial Basis 
function  
Gamma=0.33 
64.3% 64% 64.2% 
 
SVM 
2. 
ABCB1-Pgp S/3G61-
QZ59RR 
S/QZ59upper 
S/QZ59RRR 
S/Ver3g5u 
S/QZ59lower 
 
Classificatio
n type 1 
Capacity=10
.0 
Radial Basis 
function  
Gamma=0.2 
69.4% 60% 67.5% 
SVM 
3. 
ABCB1-Pgp S/QZ59RRR 
LogD(2) 
LogD(10) 
 
Classificatio
n type 1 
Capacity=3.
00 
Radial Basis 
function  
Gamma=0.3 
75.5% 76% 75.6% 
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3.3  Prediction accuracies of statistical models 
The accuracy of predictions of all models developed is shown in Table 5 below.  
The accuracy of each model, Youden’s J statistic and Matthews correlation 
coefficient (MCC) calculations were carried out to predict the accuracy of the 
models. The formulas for the calculations are also described below. 
Table 6. Results of all statistical models 
 
        Acc – Accuracy =                        SE – Sensitivity=              
        SP – Specificity=             Youdens J =                           –     
       MCC – Matthews correlation coefficient =  
                                              
TP, TN, FP, and FN are True Positive, True Negatives, False Positive and False Negative 
respectively. 
 
 
                        Training Set                 Validation Set 
Model Acc SE SP Youden’s 
J 
MCC Acc SE SP Youden’s 
J 
MCC 
CART 1  0.64 0.88 0.45 0.34 0.36 0.68 1 0.43 0.43 0.50 
CART 2 0.71 0.59 0.83 0.41 0.49 0.64 0.64 0.64 0.28 0.35 
CART 3 0.69 0.64 0.73 0.38 0.38 0.6 0.36 0.79 0.15 0.17 
CART 4 0.96 0.95 0.96 0.91 0.91 0.48 0.22 0.67 0.11 0.12 
SVM 1 0.64 0.49 0.76 0.25 0.26 0.64 0.45 0.79 0.24 0.26 
SVM 2 0.7 0.59 0.8 0.39 0.4 0.6 0.36 0.79 0.15 0.17 
SVM 3 0.76 0.67 0.82 0.49 0.5 0.81 0.72 0.93 0.65 0.65 
IT 1 0.83 0.83 0.83 0.66 0.66 0.81 0.78 0.83 0.61 0.61 
IT2 0.85 0.93 0.79 0.72 0.71 0.81 0.67 0.92 0.58 0.61 
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    Statistical Model Prediction for Validation set 
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3.3.1 Accuracy vs. Matthews correlation coefficient  
The accuracy and Matthews correlation coefficient calculations were compared 
for each model for the validation set. The result for the performance for each 
model is shown graphically below. 
Figure 16. Graph showing performance of models for validation set 
 
Overall the best model was SVM 3, due to a better performance of Youden’s J 
and MCC for the validation set. As well as this IT 1 and IT2 models also showed 
good performance for both training and validation set. 
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4. Discussion 
P-glycoprotein is a member of a super family of transporters expressed in cells of 
the liver, kidney and in the blood brain barrier. For it to function, ATP is 
required to transport molecules across cell membranes. The major role of this 
protein is to export drugs and metabolites out of cells and it has also been 
associated with multi-drug resistance in cancerous cells (Leslie, et al., 2009). The 
first objective of this study was to identify substrates and inhibitors of                
P-glycoprotein by evaluating their docking energies. At present, various studies 
have proposed a range of locations within the internal cavity of P-gp that 
compounds may bind to (Aller, et al., 2009; Gutmann, et al., 2009). To dock the 
compounds in our data set to P-gp, the binding sites of the protein had to be 
determined. Amino acid residues were selected from literature that had been 
demonstrated as binding sites of cyclic peptide inhibitors and Verapamil (Aller et 
al., 2009; Table 2) and compounds in the data set were docked to these areas.    
Docking runs were carried out for each compound in the data set using MOE 
which calculated the docking energy for each pose generated. As shown in 
Figure 5, the average docking energy at the 3G61-QZ59SSS site was lowest        
(-11.1 kcal/mol) whilst compounds docked less favourably to the 3G5U binding 
sites. Table 3 shows that the average docking energy of the top 3 scores was 
superior at the binding site defined by 3G61-QZ59-SSS but average docking 
energy of the top three scores at the Verapamil site was -13.6 kcal/mol.  These 
results showed that docking performance for compounds in the data set was 
considerably better when docked to the co-crystallised ligand in P-gp 3G61. 
Better docking performance in 3G61 could be due to the changed confirmation 
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Figure 17 Location of QZ59 compounds in Pgp drug binding pocket. A. One QZ59-
RRR molecule  B. Two QZ59-SSS molecules.  (Aller , et al., 2009) 
 
of the protein upon ligand binding in accordance with the induced fit binding 
theory (Alonso, et al., 2006).  
 By docking to 3G61 (Figure 17), compounds were able to interact with more 
residues compared with other sites thus improving their chances of binding to the 
protein. 
               A                                                                       B                      
  
 
 
 
  
 
A list of compounds with strong affinity for the binding sites of P-gp is shown in 
Table 4. Cyclosporin an immunosuppressant drug, was one of the compounds in 
the data set that had significantly better docking scores across all binding sites. 
As shown in Table 4, docking energy of Cyclosporin was lowest at 3G61 
compared to other sites. As well as this, Rifampicin best docking energy at the 
QZ59-SSS upper site was -14.776971kcal/mol, and docking score at 3G61 was    
-15.8kcal/mol. Similarly, Bromosulfalein which had efficient docking 
performance across all binding sites had its lowest docking score when docked to 
3G61 (Table 4).  
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This further suggests that docking to the ligand QZ59-SSS in P-gp-3G61 was the 
most favourable binding site for compounds in our data set compared with other 
binding sites that were used.  As part of this study, it was also our aim to gain an 
understanding about the residues that play a major role in drug binding to P-gp. 
The differences in amino acid residues used at each binding site provides 
valuable information about the importance of some specific residues involved in 
drug binding to P-gp.  The amino acid residues selected for each binding site 
were reported to be within the drug binding pocket of P-glycoprotein (Aller, et 
al., 2009). Some of the residues in particular binding sites appear to play a more 
important role in drug binding compared to others. An example of this is Tyr 303 
a residue in TM helice 5 of P-gp, is part of the QZ59-RRR and QZ59-SSS 
(lower) site but not seen in the other two binding sites used. As well as this, Phe 
332 is a residue in the QZ59-RRR and QZ59-SSS (upper) sites but not in the 
Verapamil binding site (Table 2). In addition to differences such as these, some 
residues appear to be involved in all binding sites used. For example, Phe 724 
and Val 978 are part of each binding site and this suggests that they are important 
residues involved in the interaction of substrates with P-gp.   
From Table 2, it can be seen that there are several other amino acid residues that 
are involved in binding compounds to the QZ59-RRR and QZ59-SSS sites. 
Examples of these residues include, Phe 339 (TM6), Gln 721 (TM7) which are in 
both QZ59 sites whilst residues such as Ala 981(TM12) and Leu 335 (TM6) are 
identifiable in both Verapamil and QZ59-RRR sites respectively. These 
observations suggest that different transmembrane helices are involved in drug 
binding and compounds use unique segments of the transmembrane domains to 
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bind to P-gp.  It is also interesting to note the overlap of residues involved in 
drug-binding, which suggests that compounds in the data set may have similar or 
overlapping binding sites with other compounds (Ambudkar, et al., 2003).  
To illustrate this, Rifampicin a bactericidal antibiotic was seen to demonstrate 
good docking performance across both QZ59 sites and when docked to P-gp 
3G61 (Table 4). In contrast, when docked to the Verapamil binding site its best 
docking score was -10.88kcal/mol. As well as this,  Erythromycin a macrolide 
antibiotic docked in a similar way to Rifampicin at the QZ59-SSS (lower) and 
QZ59-RRR sites but not as successfully to the Verapamil site (-11.14 kcal/mol). 
It could be suggested that the docking performance at these sites, is due to both 
compounds binding to the same or overlapping residues at these binding sites.  
In addition to docking results observed, Figure 6 shows the difference between 
docking energies of substrates and non-substrates. The results here add further 
evidence to the reports that P-gp is a polyspecific protein which is capable of 
recognising different types of compounds as non-substrates were able to dock to 
P-glycoprotein. The results suggest that non-substrates in the data set are capable 
of binding to P-gp but have a weaker binding affinity. Despite these outcomes, 
limitations of the docking method discussed below should be considered when 
evaluating docking results.   
The use of X-ray structures of 3G5U and 3G61in this study as docking targets 
may have had an influence on the accuracy of docking results produced. Apart 
from the fact that one of these structures belongs to the protein co-crystallised 
with a ligand and the other is free of a ligand, the resolutions of the crystal 
structures of P-gp models used is an important factor; 3.80Å and 4.35Å for 
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3G5U and 3G61 respectively. Generally, high resolution models of proteins are 
those considered as having a resolution lower or equal to 1.5Å, whilst low 
resolution models have values greater than 2.5Å (Davis, et al., 2003). In this 
case, the X-ray structures used in this study are of low resolution and therefore 
the accuracy of these structures is still uncertain. Structural models obtained at 
higher resolutions are more likely to produce better docking results (Mohan et al, 
2005). This is because higher resolution models are developed using more 
experimental data whereas at lower resolutions, models are likely to be more 
subjective and include a greater number of errors (Davis, et al., 2003; Davis, et 
al., 2008). Consequently, docking results from this study may not be 
reproducible because we cannot be sure that the 3D structural models of P-gp are 
correct and validated. 
Additionally, the scoring method used to calculate binding energies of the 
compounds would have had a major impact on the docking results. During the 
docking process, the top 30 poses produced after placement were scored using 
the London dG scoring function. As an empirical scoring function, it calculates 
the binding energy of compounds based on the sum of independent reactions 
from experimental data (Lipkowitz and Boyd, 2002).  The issue with this is that 
the experimental data used to derive the scoring function may not be consistent 
with the data set used in this study therefore inaccuracies in scoring are likely. 
Furthermore, the scoring function is also more inclined to favour larger 
compounds.  
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Due to the additive nature of the formula, larger compounds are more likely to 
have better docking energies than smaller compounds (Schulz-Gasch and Stahl, 
2004; Lipkowitz and Boyd, 2002).  This is reflected in the results produced as 
compounds with high docking performance (Table 4) e.g. Bromosulfalein, 
Ivermectin A, Rifampicin, (794.03g mol
-1
, 875.09g mol
-1
 and 822.94g mol
-1
) 
were part of the heaviest compounds in the data set. In contrast, smaller 
compounds such as Valproic Acid (144.21 g mol
-1
) and Amantadine (151.25 g 
mol
-1
) had average docking scores of -7.04kcal/mol and -6.37kcal/mol 
respectively (Appendix 3).  
The lack of flexibility of the target protein used in docking should also be taken 
into consideration when assessing docking results. The main purpose of the dock 
application in MOE, is to calculate docking energies between a rigid protein 
target and flexible ligand.  The inflexible nature of the protein during docking 
highlights the fact that in-silico methods do not totally represent what occurs in 
biological systems.  For docking results to successfully guide our predictions of 
inhibitors and substrates of P-gp, it should take into account the flexible nature of 
the receptor. Previous studies have described the importance of protein flexibility 
in P-gp ligand interactions (Davis, et al. , 1999; Teague, 2003; Loo, et al. , 2003; 
Loo, et al. , 2009) and the induced-fit mechanism that drives this phenomenon.  
Induced fit mechanism explains the fact that both drug and protein are flexible, 
and can modify their shape to generate more favourable contacts (Alonso, et al., 
2006). Current evidence demonstrates that P-glycoprotein is able to 
accommodate a wide range of substrates due to the mobile nature of its 
transmembrane helices (Ambudkar, et al., 2003; Loo, et al., 2003). From this 
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hypothesis, it is possible that compounds in the data set may not be correctly 
identified as substrates or inhibitors of P-gp, because the docking process does 
not allow the protein to be mobile and therefore some compounds are not 
recognised as a substrate in the drug binding pocket.  Further to this, the use of 
only specific binding sites in the drug binding pocket did not allow us to fully 
explore the diverse nature of P-glycoprotein. Using only the QZ59 and 
Verapamil binding sites meant that compounds could only dock to these areas. It 
is possible that variable docking energies may have been produced if compounds 
were docked to other residues of P-gp (Gutmann, et al., 2009).  
The aim of docking the data set of 123 compounds was to find out if scoring 
functions can correctly identify the substrates and non-substrates of the data set. 
After obtaining docking results from each binding site, statistical models were 
built using data mining tools in Statistica to explore the classification accuracy of 
the docking scores. In each classification tree built, the classification of 
compounds as substrates/non-substrates was used as the dependent variable.  The 
CART 2 model was built using docking scores from each binding site as 
independent variables. By examining CART 2, it shows us that docking scores at 
QZ59-RRR site were of importance and that if docking energy is lower than        
-9.26423kcal/mol, compounds are classified as substrates.  
 The tree was further split according to the docking score at QZ59-SSS (upper) 
site, with substrates classified as those having docking scores above                     
-11.383177kcal/mol. The final node of this tree established that compounds with 
docking energy below -9.039293kcal/mol at QZ59-SSS (lower) site are 
substrates of P-glycoprotein. The disparity in the final two nodes may be related 
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to the differences in amino acid residues at each site and the fact that some 
compounds have overlapping binding sites (Ambudkar, et al., 2003) hence their 
binding to P-glycoprotein extends beyond the QZ59-SSS (upper) site. 
The CART 3 model was built using docking scores and RMSD scores at the 
QZ59-SSS site of 3G61. This was performed because average docking scores for 
compounds in the data set was much better at this site. Consequently, the tree 
was split into three nodes with docking score being most important. The tree was 
then split according to RMSD scores and defined substrates as those having an 
RMSD below 2.18120kcal/mol as a substrate. Substrates meeting this criteria 
were also classified as a substrate if their docking score was lower than                 
-11.092090kcal/mol in the final node of the tree.  
 A further tree was developed to detect the most important factor for P-gp 
binding, by combining docking scores and molecular descriptors calculated by 
ACD Labs. A total of 320 molecular descriptors were available. The model built 
using these variables (CART 4), selected LogP as the main descriptor required 
for P-gp binding. Substrates were classified as having a LogP above 2.67 and 
were further classified as substrates by various descriptors such as ionization 
potential and sum of Van der Waals surface area. Average LogP of compounds 
in the data set was 2.91 and 56% of compounds in the data set had a LogP value 
above 2.67. From this classification tree, it can be suggested that lipophilicity is 
an essential part of a compounds ability to bind to P-gp.   
This is in agreement with previous studies that have described LogP as an 
important parameter in drug binding to P-gp (Wang, et al., 2003; Matsson, et al., 
2009; Aller, et al., 2009). The significance of LogP for this data set is due to the 
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location of the residues in the binding sites.  Amino acid residues in the binding 
sites were mostly located in the upper section of P-gp and this area purportedly 
contains hydrophobic and aromatic residues (Aller, et al., 2009). Therefore, it is 
likely that lipophilic substrates will bind to P-gp using these residues.  It is also 
considerable that Van der Waals surface area factors, (SMR_VSA2, SMR_VSA7, 
and VSA) were also used to determine the classification of compounds.  
The cyclic peptide inhibitors used to detect binding sites in P-glycoprotein, 
mainly interacted with residues by hydrophobic and Van der Waals interactions 
(Aller et al, 2009). Compounds in this data set seem to follow that trend 
according to CART 4 and it is has also been suggested that drug binding to P-gp 
is associated with compounds Van der Waals surface area (Litman, et al., 1997).  
Despite combining docking scores with molecular descriptors to build CART 4 
model, molecular descriptors were selected as being of importance rather than 
the docking energy. From this outcome, it can be suggested that molecular 
descriptors are better predictors of a compounds class as a substrate or non-
substrate. 
After assessing results of the classification trees, Interaction trees were also 
developed (Figure 14 & 15). In each tree developed, one variable was manually 
selected as being of importance for the first splitting criteria and then the 
software statistically selected other variables to grow the tree. In both trees, the 
software selected LogD(2) and LogD(10) as other important attributes for 
classification of substrates and non-substrates. This is in accordance with 
suggestions that lipophilicity plays a major role in P-gp activity. 
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SVM models were then developed to further classify substrates and non-
substrates of P-glycoprotein (Table 5). SVM 1 was built using docking scores 
from 3G61, QZ59 (upper) and QZ59-RRR sites of 3G5U. This model had an 
overall accuracy of 64.2% whereas SVM 2 had an improved accuracy of 67.5% 
when using all docking scores.  SVM 3 model had an overall accuracy of 75.6% 
and this was based on docking score at the QZ59-RRR site of 3G5U and 
LogD(2) and LogD(10).  LogD was used to develop this model because it was a 
valuable descriptor selected by the Interaction trees developed (Figure 14 & 15). 
In the validation set, there are 5 substrates and 1 non substrate that had been 
misclassified by SVM 3 model; Apigenin, Imatinib, Prednisone, Progesterone, 
Quercetin, Taurocholate (Appendix 5).  Out of this group, Progesterone a non-
substrate was classified as a substrate by the SVM model. It is possible that it 
was classed as a substrate by the SVM model due to its high lipophilicity    
(LogP = 3.83), which has previously been discussed as an important property of 
P-gp substrates.  Further complementing this are suggestions that Progesterone is 
a substrate by an induced fit mechanism (Loo, et al., 2003). However, differences 
in data preparation and method used for classification indicate that the 
identification of Progesterone as a substrate or non-substrate is still uncertain in 
the literature. Other compounds that were misclassified include Apigenin and 
Quercetin which are Flavanoids that have been classified as non-substrates by 
SVM.  Similar to progesterone, misclassification could have occurred based on 
lipophilicity with both compounds exhibiting low LogP values (Appendix 3). 
Results from the Matsson study, suggest that flavanoids interact with the ATP- 
binding region of P-gp (Matsson, et al., 2009). Compounds did not interact with 
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this segment of P-gp during docking and so it could be suggested that these two 
compounds were misclassified by the model as a result of this. Overall, Table 6 
shows a summary of accuracy performance by all models and this shows that the 
best performing model was SVM 3, due to a better performance of Youden’s J 
and MCC for the validation set.  
In addition to limitations discussed previously, accuracy of the models developed 
in this study could have been improved if a larger data set was used. A larger 
dataset would have provided more valuable information and this is necessary to 
build models of better quality (Chen, et al., 2011).  Using the data set from the 
Matsson paper will have affected results as the data collected in this paper was 
based on human P-gp, whilst the structures used for docking are of mouse P-gp 
which has 87% sequence identity to human p-glycoprotein (Aller, et al., 2009). 
By forming a data set in this way reduces the reliability of the data set and 
therefore the class of compounds should be checked against other sources. 
Finally, docking energies were only calculated using one docking program. It 
would have been interesting to compare docking energies using other docking 
software such as Glide, Gold and FlexX. 
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Conclusions 
In this study, a data set of 123 compounds was docked to P-gp structures 
available from the protein data bank.  Docking results revealed that compounds 
had better docking performance at the QZ59-SSS binding site in P-gp 3G61 
rather than the binding sites in 3G5U. The amino acid residues involved in all 
sites showed that some amino acid residues overlap and this suggests that 
compounds may have the same or overlapping residues in their binding sites. 
This also complements other studies, which suggest that   P-gp is a polyspecific 
protein, in which a diverse range of compounds are able to bind to it. However, it 
is important to understand that the structures described by Aller et al, merely 
represent the authors view of the P-gp structure obtained in their study. For this 
reason, we should consider that the accuracy of this structure is still uncertain 
and coupled with the relatively low resolution of the structure, the use of these 
protein structures for docking is limited.  
Despite this, results from this study do provide evidence about the amino acid 
residues that are important in drug binding e.g. Phe 724 and Val 978. In addition 
to this, docking results appear to be better when the protein structure 
conformation has already been changed in order to allow binding of a ligand as 
was observed from docking results of    P-gp 3G61 co-crystallised with QZ59-
SSS. Other significant results from this study also show that LogP is a major 
contributor to compounds availability and compounds with high LogP are more 
likely to be able to bind to P-glycoprotein.   
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Future work 
The findings from this study do allow us to propose suggestions for future work. 
Amino acid residues that were part of all binding site sequences Phe 724 and Val 
978 could possibly be a target for inhibitors of P-glycoprotein. These residues 
appear to be vital for P-gp interactions and inhibitors could aim to covalently 
bind to residues such as these, therefore disrupting P-gp function.  The lack of 
high resolution models has severely limited work in this field but if higher 
resolution models of P-gp were made available, this would greatly improve the 
identification of binding sites within P-glycoprotein. Higher resolution models 
will also improve docking energies and allow us to visualise the interactions 
between P-gp and compounds. After combining docking scores and molecular 
descriptors to build models in this study, this could possibly be the way forward 
in improving identification of P-gp substrates and inhibitors. By using docking 
results, molecular descriptor calculations and results from other in-silico methods 
such as QSAR and pharmacophore modelling, this may provide better outcomes 
for identification of P-gp substrates and inhibitors. Although this may prove 
challenging, there are studies which suggest that combining methods together to 
build a global model can be beneficial (Li, et al., 2007; Pajeva, et al., 2009). 
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APPENDIX 
Appendix 1: SMILES CODE 
Compound SMILES CODE 
Chlorprotixene Clc2cc1C(\c3c(Sc1cc2)cccc3)=C/CCN(C)C 
Cyclosporine-A O=C1N(C)[C@H](C(=O)N[C@H](C(=O)N(C)CC(=O)N(C)[C@H](C(=O)N[C
@H](C(=O)N(C)[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(
=O)N(C)[C@H](C(=O)N(C)[C@H]1C(C)C)CC(C)C)CC(C)C)C)C)C)CC(C)C)
C(C)C)CC(C)C)CC)[C@H](O)[C@H](C)C/C=C/C 
Diethylstilbestrol  Oc2ccc(/C(=C(/c1ccc(O)cc1)CC)CC)cc2 
Dipyridamole n3c(nc2c(nc(nc2N1CCCCC1)N(CCO)CCO)c3N4CCCCC4)N(CCO)CCO 
Flupentixol FC(F)(F)c2cc1C(\c3c(Sc1cc2)cccc3)=C/CCN4CCN(CCO)CC4 
GF120918 O=C2c1cccc(c1Nc3c2cccc3OC)C(=O)Nc4ccc(cc4)CCN6Cc5c(cc(OC)c(OC)c5)
CC6 
Isradipine O=C(OC)\C3=C(\N\C(=C(\C(=O)OC(C)C)C3c1cccc2nonc12)C)C 
Ivermectin A CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@@H]2[C@@H](OC)
C[C@@H](O[C@H]2C)O[C@@H]3C(C)=CC[C@@H]6C[C@H](OC(=O)[C
@@H]4C=C(C)[C@@H](O)[C@H]5OCC(=CC=C[C@@H]3C)[C@@]45O)C[
C@@]7(O6)CC[C@H](C)[C@H](O7)[C@@H](C)CC 
Ivermectin B CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@@H]2[C@@H](OC)
C[C@@H](O[C@H]2C)O[C@@H]3C(C)=CC[C@@H]6C[C@H](OC(=O)[C
@@H]4C=C(C)[C@@H](O)[C@H]5OCC(=CC=C[C@@H]3C)[C@@]45O)C[
C@@]7(O6)CC[C@H](C)[C@H](O7)C(C)C 
Loperamide Clc1ccc(cc1)C4(O)CCN(CCC(c2ccccc2)(c3ccccc3)C(=O)N(C)C)CC4 
Lopinavir O=C(N[C@@H](Cc1ccccc1)[C@@H](O)C[C@@H](NC(=O)[C@@H](N2C(=
O)NCCC2)C(C)C)Cc3ccccc3)COc4c(cccc4C)C 
MK571  CN(C)C(=O)CCSC(SCCC(=O)O)c1cccc(c1)/C=C/c2ccc3ccc(Cl)cc3n2 
Quercetin O=C1c3c(O/C(=C1/O)c2ccc(O)c(O)c2)cc(O)cc3O 
Reserpine O=C(OC)[C@H]6[C@H]4C[C@@H]3c2nc1cc(OC)ccc1c2CCN3C[C@H]4C[C
@@H](OC(=O)c5cc(OC)c(OC)c(OC)c5)[C@@H]6OC 
Ritonavir CC(C)c4nc(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccccc1)C[C
@H](O)[C@H](Cc2ccccc2)NC(=O)OCc3cncs3)cs4 
Saquinavir  O=C(N)C[C@H](NC(=O)c1nc2c(cc1)cccc2)C(=O)N[C@@H](Cc3ccccc3)[C@
H](O)CN5[C@H](C(=O)NC(C)(C)C)C[C@@H]4CCCC[C@@H]4C5 
Silymarin  O=C4c5c(O)cc(O)cc5O[C@H](c2ccc1O[C@H]([C@@H](Oc1c2)c3ccc(O)c(O
C)c3)CO)[C@H]4O 
Tamoxifen  O(c1ccc(cc1)/C(c2ccccc2)=C(\c3ccccc3)CC)CCN(C)C 
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Terfenadine  OC(c1ccccc1)(c2ccccc2)C4CCN(CCCC(O)c3ccc(cc3)C(C)(C)C)CC4 
Thioridazine S(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C 
Benzbromarone Brc1cc(cc(Br)c1O)C(=O)c2c3ccccc3oc2CC 
Amiodarone Ic1cc(cc(I)c1OCCN(CC)CC)C(=O)c2c3ccccc3oc2CCCC 
Apigenin O=C\1c3c(O/C(=C/1)c2ccc(O)cc2)cc(O)cc3O 
17ß-estradiol  C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)
O 
Biochanin A O=C\1c3c(O/C=C/1c2ccc(OC)cc2)cc(O)cc3O 
Chlorpromazine CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)Cl 
Chrysin O=C\1c3c(O/C(=C/1)c2ccccc2)cc(O)cc3O 
Ergocristine  O=C3N1CCC[C@H]1[C@]2(O)O[C@](C(=O)N2[C@H]3Cc4ccccc4)(NC(=O)[
C@@H]8/C=C7/c5cccc6c5c(cn6)C[C@H]7N(C)C8)C(C)C 
Felodipine  O=C(OCC)\C1=C(\N/C(=C(/C(=O)OC)C1c2cccc(Cl)c2Cl)C)C 
Gefitinib  COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F 
Genistein Oc1ccc(cc1)C\3=C\Oc2cc(O)cc(O)c2C/3=O 
Glibenclamide COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)Nc3ccccc3 
Imatinib Cc3ccc(cc3Nc1nc(ccn1)c2cccnc2)NC(=O)c4ccc(cc4)CN5CCN(C)CC5 
Ketoconazole  O=C(N5CCN(c4ccc(OC[C@@H]1O[C@](OC1)(c2ccc(Cl)cc2Cl)Cn3ccnc3)cc4
)CC5)C 
Kol 43 O=C(OC(C)(C)C)CC[C@@H]1NC(=O)[C@H]4N(C1=O)[C@H](c3c(c2ccc(O
C)cc2n3)C4)CC(C)C 
Medroxyprogesterone O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@](O)(C(=O)C)CC[C@H]3[C@
@H]1C[C@@H]2C)C)(C)CC4 
Mifepristone O=C5\C=C4/C(=C3/[C@@H](c1ccc(N(C)C)cc1)C[C@]2([C@@H](CC[C@]2(
C#CC)O)[C@@H]3CC4)C)CC5 
Nicardipine O=C(OCCN(Cc1ccccc1)C)\C2=C(\N/C(=C(/C(=O)OC)C2c3cccc([N+]([O-
])=O)c3)C)C 
Nitrendipine  O=C(OCC)\C1=C(\N/C(=C(/C(=O)OC)C1c2cccc([N+]([O-])=O)c2)C)C 
Simvastatin O=C(O[C@@H]1[C@H]3C(=C/[C@H](C)C1)\C=C/[C@@H]([C@@H]3CC[C
@H]2OC(=O)C[C@H](O)C2)C)C(C)(C)CC 
Tipranavir CCC[C@]1(CC(/O)=C(\C(=O)O1)[C@H](CC)c3cccc(NS(=O)(=O)c2ccc(cn2)C
(F)(F)F)c3)CCc4ccccc4 
Verapamil N#CC(c1cc(OC)c(OC)cc1)(CCCN(CCc2ccc(OC)c(OC)c2)C)C(C)C 
Diltiazem O=C2N(c3c(S[C@@H](c1ccc(OC)cc1)[C@H]2OC(=O)C)cccc3)CCN(C)C 
Taurolithocholic acid  C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@
H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C 
Haloperidol c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F 
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Maprotiline  c1ccc3c(c1)C4c2ccccc2C3(CC4)CCCNC 
Noscapine O=C2OC(c1ccc(OC)c(OC)c12)C5N(C)CCc4c5c(OC)c3OCOc3c4 
Prednisone  O=C(CO)[C@@]3(O)CC[C@H]2[C@@H]4CC\C1=C\C(=O)\C=C/[C@]1(C)[
C@H]4C(=O)C[C@@]23C 
Procyclidine OC(c1ccccc1)(CCN2CCCC2)C3CCCCC3 
Propafenone O=C(c1ccccc1OCC(O)CNCCC)CCc2ccccc2 
Quinidine O(c4cc1c(nccc1[C@H](O)[C@@H]2N3CC[C@@H](C2)[C@@H](/C=C)C3)cc
4)C 
Quinine  O(c4cc1c(nccc1[C@@H](O)[C@H]2N3CC[C@@H](C2)[C@@H](/C=C)C3)cc
4)C 
Taurocholate C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](
C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C 
Tetracycline CN(C)[C@@H]2C(\O)=C(\C(N)=O)C(=O)[C@@]3(O)C(/O)=C4/C(=O)c1c(ccc
c1O)[C@@](C)(O)C4CC23 
Vinblastine O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@H](C3)C4)c5c(O
C)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[
C@@]7(/C=C\CN([C@@H]78)CC9)CC 
Amodiaquine  Clc1cc2nccc(c2cc1)Nc3cc(c(O)cc3)CN(CC)CC 
Fumitremorgin C  O=C4N5[C@H](C(=O)N3[C@H](c2c(c1ccc(OC)cc1n2)C[C@H]34)\C=C(/C)C)
CCC5 
Hoechst 33342 CCOc1ccc(cc1)c2[nH]c3cc(ccc3n2)c4[nH]c5cc(ccc5n4)N6CCN(CC6)C 
Mitoxantrone O=C2c1c(c(NCCNCCO)ccc1NCCNCCO)C(=O)c3c2c(O)ccc3O 
Naringenin O=C2c3c(O[C@H](c1ccc(O)cc1)C2)cc(O)cc3O 
Omeprazole O=S(c2nc1ccc(OC)cc1n2)Cc3ncc(c(OC)c3C)C 
Prazosin O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)c4occc4 
Progesterone O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@H](C(=O)C)CC[C@H]3[C@@
H]1CC2)C)(C)CC4 
Bromosulfalein c1cc(c(cc1/C(=C/2\C=CC(=O)C(=C2)S(=O)(=O)[O-
])/c3c(c(c(c(c3Br)Br)Br)Br)C(=O)O)S(=O)(=O)[O-])O 
Lansoprazole FC(F)(F)COc1c(c(ncc1)CS(=O)c3nc2ccccc2n3)C 
P-aminohippuric acid O=C(c1ccc(N)cc1)NCC(=O)O 
Rifampicin CN1CCN(CC1)/N=C/c2c(O)c3c5C(=O)C4(C)O/C=C/C(OC)C(C)C(C(C)C(O)C(
C)C(O)C(C)\C=C\C=C(\C)C(=O)Nc2c(O)c3c(O)c(C)c5O4)C(=O)OC 
1-methyl-4-
phenylpyridinium 
c2cc(c1cc[n+](cc1)C)ccc2 
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4-Methylumbelliferone 
glucuronide 
O=C/2Oc1cc(O)ccc1\C(=C\2)C 
Amantadine  C1C2CC3CC1CC(C2)(C3)N 
Amiloride Clc1nc(C(=O)\N=C(/N)N)c(nc1N)N 
Amitriptyline  c3cc2c(/C(c1c(cccc1)CC2)=C\CCN(C)C)cc3 
Antipyrine O=C2\C=C(/N(N2c1ccccc1)C)C 
Atropine CN3[C@H]1CC[C@@H]3C[C@@H](C1)OC(=O)C(CO)c2ccccc2 
Budesonide O=C\1\C=C/[C@]2(/C(=C/1)CC[C@H]3[C@H]4[C@](C[C@H](O)[C@H]23)(
[C@@]5(OC(O[C@@H]5C4)CCC)C(=O)CO)C)C 
Captopril O=C(O)[C@H]1N(C(=O)[C@H](C)CS)CCC1 
Carbamazepine c1ccc2c(c1)C=Cc3ccccc3N2C(=O)N 
Carnitine [O-]C(=O)C[C@@H](O)C[N+](C)(C)C 
Cefamandole O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnnn
4C)C(=O)O 
Chloroquine Clc1cc2nccc(c2cc1)NC(C)CCCN(CC)CC 
Chlorzoxazone  Clc2cc1c(OC(=O)N1)cc2 
Cholic acid  C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]
2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C 
Cimetidine N#CN\C(=N/C)NCCSCc1ncnc1C 
Colchicine O=C(N[C@@H]3C\1=C\C(=O)C(\OC)=C/C=C/1c2c(cc(OC)c(OC)c2OC)CC3)
C 
Dehydroisoandrosterone
-3-sulfate 
O=S(=O)(O)O[C@@H]4C/C3=C/C[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C
@H]12)C)[C@@]3(C)CC4 
Desipramine  c1cc3c(cc1)CCc2c(cccc2)N3CCCNC 
Digoxin O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]7[C@
H]8CC[C@H]6[C@]7(C)CC[C@H](O[C@@H]5O[C@H](C)[C@@H](O[C@
@H]4O[C@@H]([C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](O)
C3)C)[C@@H](O)C4)C)[C@@H](O)C5)C6 
Doxorubicin C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)
C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O 
Erythromycin  CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([
C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O
2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C
)C)O)(C)O 
Estradiol-17ß-
glucuronide  
O=C(O)[C@@H]5OC(O[C@H]4CC[C@@H]2[C@]4(C)CC[C@@H]1c3ccc(O
)cc3CC[C@H]12)[C@@H](O)[C@H](O)[C@H]5O 
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Etoposide C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@
@H]3c4cc5c(cc4[C@H]([C@@H]6[C@@H]3COC6=O)c7cc(c(c(c7)OC)O)OC
)OCO5)O)O 
Fexofenadine  O=C(O)C(c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4)(C)C 
Flucloxacillin O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1c(F)cccc1Cl)C)[C@H
]4SC3(C)C 
Hydrochlorothiazide O=S(=O)(c1c(Cl)cc2c(c1)S(=O)(=O)NCN2)N 
Hydrocortisone  O=C4\C=C2/[C@]([C@H]1[C@@H](O)C[C@@]3([C@@](O)(C(=O)CO)CC[
C@H]3[C@@H]1CC2)C)(C)CC4 
Indinavir CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](Cc2ccccc2)C(=O)
N[C@H]3c4ccccc4C[C@H]3O)O)Cc5cccnc5 
Indomethacin  Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O 
Mesalazine O=C(O)c1cc(ccc1O)N 
Methotrexate  O=C(O)[C@@H](NC(=O)c1ccc(cc1)N(C)Cc2nc3c(nc2)nc(nc3N)N)CCC(=O)O 
Metoprolol  O(c1ccc(cc1)CCOC)CC(O)CNC(C)C 
Nevirapine  O=C2Nc1c(ccnc1N(c3ncccc23)C4CC4)C 
Nicotine n1cc(ccc1)[C@H]2N(C)CCC2 
Ofloxacin Fc4cc1c2N(/C=C(\C1=O)C(=O)O)C(COc2c4N3CCN(C)CC3)C 
Phenobarbital CCC1(C(=NC(=O)N=C1O)O)c2ccccc2 
Phenylethyl 
isothiocyanate 
S=C=N/CCc1ccccc1 
Phenytoin  O=C2NC(=O)NC2(c1ccccc1)c3ccccc3 
Pravastatin O=C(O)C[C@H](O)C[C@H](O)CC[C@H]2[C@H](/C=C\C1=C\[C@@H](O)C
[C@H](OC(=O)[C@@H](C)CC)[C@@H]12)C 
Prednisolone  O=C\1\C=C/[C@]4(/C(=C/1)CC[C@@H]2[C@@H]4[C@@H](O)C[C@@]3([
C@@](O)(C(=O)CO)CC[C@@H]23)C)C 
Probenecid O=S(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1 
Propranolol CC(C)NCC(COc1cccc2c1cccc2)O 
Ranitidine  [O-][N+](=O)\C=C(\NC)NCCSCc1oc(cc1)CN(C)C 
Sotalol O=S(=O)(Nc1ccc(cc1)C(O)CNC(C)C)C 
Sparfloxacin C[C@@H]1CN(C[C@@H](N1)C)c2c(c(c3c(c2F)n(cc(c3=O)C(=O)O)C4CC4)N
)F 
Sulfasalazine O=S(=O)(Nc1ccccn1)c3ccc(/N=N/c2cc(C(O)=O)c(O)cc2)cc3 
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Sulfinpyrazone O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4 
Sulindac O=S(c1ccc(cc1)\C=C3/c2ccc(F)cc2\C(=C3C)CC(=O)O)C 
Testosterone  O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@H](O)CC[C@H]3[C@@H]1CC
2)C)(C)CC4 
Tinidazole [O-][N+](=O)c1cnc(n1CCS(=O)(=O)CC)C 
Trimethoprim  COc1cc(cc(c1OC)OC)Cc2cnc(nc2N)N 
Valproic acid  O=C(O)C(CCC)CCC 
Warfarin  CC(=O)CC(C\1=C(/O)c2ccccc2OC/1=O)c3ccccc3 
Vincristine O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@@H](C3)C4)c5c(
OC)cc6c(c5)[C@@]89[C@@H](N6C=O)[C@@](O)(C(=O)OC)[C@H](OC(=O
)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC 
Zidovudine O=C/1NC(=O)N(\C=C\1C)[C@@H]2O[C@@H]([C@@H](\N=[N+]=[N-
])C2)CO 
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Appendix 2: Highest docking score for each compound 
Compound ABCB1P-
gp 
S-Ver3g5u S/QZ59upper S/QZ59lower S/QZ59rrr S/3G61 
Chlorprotixene 1 -9.3004074 -8.459938 -8.1764832 -8.803051 -9.436208 
Cyclosporine-A 1 -10.156612 -13.913272 -15.671002 -16.93857 -17.60867 
Diethylstilbestrol  1 -9.4258194 -7.717423 -7.9587054 -10.264479 -9.587139 
Dipyridamole 1 -11.091798 -10.233459 -10.369469 -11.163453 -12.34627 
Flupentixol 1 -10.632503 -10.661702 -11.41256 -10.590546 -11.23787 
GF120918 1 -9.8905039 -10.713839 -9.8388119 -10.92973 -11.64353 
Isradipine 1 -10.450793 -11.525162 -10.018229 -9.8677025 -10.29302 
Ivermectin A 1 -15.407999 -17.49052 -15.053252 -14.21278 -13.68392 
Ivermectin B 1 -8.5880575 -14.182034 -15.702105 -12.753691 -11.51765 
Loperamide 1 -9.830308 -9.6608973 -10.113488 -10.485672 -12.6576 
Lopinavir 1 -10.369528 -9.2258024 -10.088408 -10.676792 -12.42869 
MK571  1 -10.548156 -12.268476 -9.7600927 -9.9758444 -12.00426 
Quercetin 1 -9.6049185 -9.846427 -9.4942179 -10.662757 -9.802873 
Reserpine 1 -9.6042442 -11.332067 -10.40928 -11.331938 -14.4181 
Ritonavir 1 -11.058732 -12.277213 -9.7571392 -10.353203 -12.82965 
Saquinavir  1 -11.114758 -10.143492 -10.06812 -9.9175653 -13.85331 
Silymarin  1 -12.211308 -12.740396 -11.329776 -12.592422 -15.67663 
Tamoxifen  1 -9.6038904 -8.5444183 -9.0636072 -10.022164 -11.78149 
Terfenadine A44 1 -10.828145 -8.8642521 -10.5563 -11.039285 -11.73056 
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Thioridazine 1 -8.9083242 -7.8792377 -10.050879 -9.5215521 -10.70159 
Benzbromarone 0 -10.346081 -8.221384 -9.9977951 -10.500174 -11.18317 
Amiodarone 1 -10.70286 -10.739605 -9.6271276 -10.519768 -12.65702 
Apigenin 1 -10.61247 -9.2287788 -8.6095076 -10.622262 -9.70258 
17β-estradiol  1 -9.3679514 -7.8578453 -9.462574 -10.319477 -8.940121 
Biochanin A 1 -9.2910938 -10.263983 -8.1855145 -8.2347078 -9.657901 
Chlorpromazine 1 -8.3345718 -7.7475543 -7.8980999 -8.9394903 -10.38405 
Chrysin 1 -10.554909 -8.3061218 -10.490614 -10.57549 -8.911892 
Ergocristine  1 -10.259492 -10.541076 -10.302964 -11.130157 -12.58193 
Felodipine  1 -9.6793785 -7.7453742 -9.5227003 -9.5240564 -10.0143 
Gefitinib  1 -10.119772 -10.34021 -9.0785007 -11.483757 -11.43558 
Genistein 1 -9.0585032 -8.3349791 -10.125244 -9.279067 -9.529384 
Glibenclamide 1 -10.019725 -11.332147 -8.7031746 -10.400661 -11.69834 
Imatinib 1 -10.306933 -10.95615 -10.700336 -10.292026 -10.45726 
Ketoconazole  1 -10.214561 -11.057756 -9.1053286 -9.9653654 -11.57038 
Kol 43 1 -8.9050388 -10.648838 -9.1451588 -10.571228 -12.40026 
Medroxyprogesterone 1 -9.6898108 -7.7250443 -9.3627224 -9.9533339 -11.0971 
Mifepristone 1 -10.505825 -9.1948147 -10.158919 -9.4235382 -13.46323 
Nicardipine 1 -10.663759 -9.9746799 -9.4923162 -10.301338 -13.60907 
Nitrendipine  1 -9.9102268 -8.5903606 -9.1928492 -9.6273088 -10.03407 
Simvastatin 1 -10.496209 -8.8446598 -9.1530542 -9.7082663 -11.98095 
Tipranavir 1 -11.627663 -10.544059 -10.162716 -11.806179 -14.14789 
Verapamil 1 -10.519194 -10.790701 -9.2990332 -8.6394806 -12.54895 
Diltiazem 1 -9.7515516 -9.5250664 -7.7090964 -9.7192259 -12.28151 
Taurolithocholic acid  1 -10.897123 -9.1023989 -10.131459 -11.243021 -12.83619 
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Haloperidol 1 -9.2387438 -10.970337 -8.5671577 -9.6470385 -11.13091 
Maprotiline  1 -9.5215988 -8.9605398 -8.6476765 -9.4146843 -9.887517 
Noscapine 1 -10.431744 -10.722205 -10.501363 -10.413963 -12.00903 
Prednisone  1 -10.309956 -10.344711 -9.5839205 -10.487357 -10.65359 
Procyclidine 1 -8.8565769 -8.4229498 -8.4684896 -8.7602282 -9.858139 
Propafenone 1 -9.1153469 -9.4176445 -8.7731705 -10.269821 -11.47182 
Quinidine 1 -9.539341 -7.6209884 -9.5094252 -9.761198 -9.330069 
Quinine A50 1 -9.3600197 -8.193058 -8.6307859 -10.090897 -11.55817 
Taurocholate 1 -10.252878 -9.6550837 -10.120589 -13.826485 -15.2546 
Tetracycline 1 -12.25106 -9.2137432 -9.9086618 -12.249457 -11.59131 
Vinblastine 1 -7.6626611 -9.919591 -11.387159 -9.285367 -13.51052 
Amodiaquine  0 -10.609269 -9.0921354 -8.8429432 -10.655272 -10.72421 
Fumitremorgin C  0 -10.10892 -9.4868574 -9.3236475 -10.058537 -10.67109 
Hoechst 33342 0 -9.6359091 -11.045726 -9.3159275 -10.280766 -11.00911 
Mitoxantrone 0 -12.069983 -11.434206 -10.387532 -10.386574 -13.87651 
Naringenin 0 -10.699261 -9.1101408 -10.72489 -10.711188 -8.341228 
Omeprazole 0 -9.6031446 -10.293558 -10.02894 -8.8998051 -9.922818 
Prazosin 0 -8.8828516 -10.613285 -9.3761845 -9.1080608 -11.63355 
Progesterone 0 -9.2005606 -8.8879795 -8.9872503 -10.076205 -10.39482 
Bromosulfalein 0 -12.974476 -12.310234 -11.747195 -12.696462 -15.77145 
Lansoprazole 0 -9.9817438 -9.4636879 -8.6808853 -9.5217371 -10.55191 
P-aminohippuric acid 0 -7.5560284 -7.3900452 -7.3223267 -7.7994919 -8.224644 
Rifampicin 0 -10.881661 -14.776971 -12.707092 -15.607213 -15.85894 
1-methyl-4-phenylpyridinium 0 -6.934773 -7.7081928 -6.4839993 -6.8460197 -7.963677 
4-Methylumbelliferoneglucuronide 0 -7.9916229 -7.8331814 -8.9206944 -7.9753709 -6.826306 
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Amantadine  0 -6.3526926 -5.3320203 -6.3266449 -6.3345504 -7.503057 
Amiloride 0 -8.8389435 -7.5056643 -7.6710935 -8.2251282 -8.684454 
Amitriptyline A98 0 -9.2818766 -8.9655581 -9.3389559 -9.2117443 -9.565305 
Antipyrine 0 -7.3381066 -6.6651206 -7.3842626 -7.571815 -7.122243 
Atropine 0 -9.0077009 -8.051362 -8.3661737 -8.9017839 -9.776143 
Budesonide 0 -11.293019 -11.60719 -9.1883268 -9.7388487 -11.08708 
Captopril 0 -7.6405721 -8.0399799 -8.0298433 -8.188179 -7.657503 
Carbamazepine 0 -8.5274229 -7.2034917 -8.4886007 -9.3757973 -9.013274 
Carnitine 0 -7.2166624 -7.0989256 -6.9449291 -6.4096179 -8.174127 
Cefamandole 0 -10.145037 -10.903329 -10.494161 -12.38217 -12.55593 
Chloroquine 0 -9.532608 -9.0205898 -8.1266356 -9.2494192 -9.54703 
Chlorzoxazone  0 -7.3827214 -6.3034315 -6.025938 -7.3652225 -7.332795 
Cholic acid  0 -10.776716 -8.9253407 -8.5485239 -10.711271 -12.42511 
Cimetidine 0 -7.7259474 -7.2465606 -8.2314672 -8.4074793 -8.449764 
Colchicine 0 -10.714324 -12.727611 -10.133555 -11.653122 -11.96499 
Dehydroisoandrosterone-3-sulfate 0 -9.270402 -10.271486 -8.6834316 -9.9046402 -11.77644 
Desipramine  0 -8.9099407 -9.0193939 -8.8133793 -8.9883986 -9.752567 
Digoxin 0 -11.16558 -15.264123 -13.845214 -12.67726 -14.25247 
Doxorubicin 0 -12.270447 -9.7047529 -12.654102 -12.111775 -14.87355 
Erythromycin  0 -11.146794 -12.131126 -12.796752 -12.736913 -13.13491 
Estradiol-17β-glucuronide A66 0 -11.490866 -10.448287 -10.062901 -11.392282 -14.00624 
Etoposide 0 -11.064533 -11.451082 -10.737698 -12.774714 -15.36379 
Fexofenadine  0 -10.728499 -12.205088 -9.9871464 -11.987885 -10.3285 
Flucloxacillin 0 -11.07047 -9.6187134 -9.8800745 -10.685433 -11.20973 
Hydrochlorothiazide 0 -8.4825487 -8.925005 -8.2919388 -8.507925 -9.363761 
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Hydrocortisone  0 -10.304188 -9.6608438 -9.8306179 -10.031824 -10.60378 
Indinavir 0 -9.6872206 -11.956147 -9.8693228 -11.337888 -12.38338 
Indomethacin  0 -9.4931955 -12.066354 -8.9237766 -9.7628975 -12.64803 
Mesalazine 0 -6.9549108 -7.6400247 -8.1257553 -7.9664588 -7.541798 
Methotrexate  0 -11.986519 -12.722812 -10.812212 -10.057438 -13.23796 
Metoprolol  0 -7.9435692 -9.3319874 -7.7133036 -8.3539362 -10.60786 
Nevirapine  0 -9.0224047 -8.4566927 -7.8702278 -8.9860678 -7.827874 
Nicotine 0 -6.9170685 -7.0697546 -6.1248832 -6.8440375 -7.391009 
Ofloxacin 0 -8.5635834 -10.142664 -8.5361586 -10.691373 -10.93162 
Phenobarbital  0 -9.6933594 -7.4914031 -9.5400419 -8.8618202 -8.699678 
Phenylethyl isothiocyanate 0 -6.7740951 -5.9904637 -6.1920362 -6.5109282 -7.488194 
Phenytoin  0 -8.8452339 -7.7078223 -8.1711397 -8.8362265 -8.585069 
Pravastatin 0 -10.683473 -10.081711 -8.7615652 -11.556952 -12.16104 
Prednisolone  0 -10.106754 -9.0637264 -9.5830917 -10.937309 -10.8012 
Probenecid 0 -8.9605207 -9.3834229 -8.4948893 -8.909256 -8.614807 
Propranolol 0 -9.3896971 -9.2584066 -8.6361856 -8.5617714 -10.65507 
Ranitidine  0 -8.7418537 -8.3862219 -8.4139299 -8.5178547 -9.984197 
Sotalol 0 -8.5546455 -8.9202785 -9.2301331 -8.9183006 -9.847155 
Sparfloxacin 0 -9.6356382 -10.27851 -9.5493898 -10.364615 -11.56888 
Sulfasalazine 0 -10.049615 -10.035481 -9.5956984 -10.255516 -11.54249 
Sulfinpyrazone 0 -10.12289 -9.5853405 -9.0000858 -10.790933 -11.81816 
Sulindac 0 -9.1808004 -11.152394 -9.6613617 -9.4821892 -11.10014 
Testosterone  0 -9.7777252 -7.3668432 -8.6111145 -9.8584127 -9.95339 
Tinidazole 0 -8.1798 -8.2702465 -8.0159121 -8.2341499 -9.185381 
Trimethoprim  0 -8.3030396 -10.153893 -9.2529078 -9.0906744 -9.998123 
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Valproic acid  0 -7.5599384 -6.473103 -6.8606076 -6.737505 -7.569929 
Warfarin A37 0 -10.079456 -8.9441195 -9.6533222 -9.8448915 -10.05809 
Vincristine 0 -9.6095648 -12.462447 -10.760735 -10.002497 -14.47043 
Zidovudine 0 -9.2348881 -8.7530203 -8.329999 -10.314642 -8.797813 
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Appendix 3: LogP, LogD and MW of compounds 
Substance ABCB1P-
gp 
Group S/3G61-
QZ59RR 
LogD(2) LogD(5.5) LogD(6.5) LogD(7.4) LogD(10) LogP MW 
17ß-estradiol  1 Train -8.94012 4.15 4.15 4.15 4.14 3.96 4.15 272.38 
4-
Methylumbelliferoneglucuronide 
0 Train -6.82631 2.43 2.43 2.42 2.33 0.46 2.43 176.17 
Amantadine  0 Train -7.50306 -0.66 -0.66 -0.63 -0.47 1.62 2.44 151.25 
Amiloride 0 Train -8.68445 0.76 1.22 1.22 1.22 1.22 1.22 229.63 
Amiodarone 1 Train -12.657 4.71 4.78 5.14 5.87 7.72 7.81 645.31 
Amitriptyline  0 Train -9.5653 1.31 1.41 1.87 2.64 4.35 4.41 277.4 
Amodiaquine  0 Train -10.7242 -0.96 0.0236 0.31 0.95 2.36 3.13 355.86 
Atropine 0 Train -9.77614 -1.72 -1.7 -1.57 -1.09 1.09 1.38 289.37 
Benzbromarone 0 Train -11.1832 6.65 5.75 4.82 4.05 3.5 6.65 424.08 
Biochanin A 1 Train -9.6579 3.34 3.28 2.93 2.11 -0.77 3.34 284.26 
Bromosulfalein 0 Train -15.7715 -3.67 -4.04 -4.04 -4.06 -4.89 1.46 794.03 
Budesonide 0 Train -11.0871 3.2 3.2 3.2 3.2 3.2 3.2 430.53 
Captopril 0 Train -7.6575 1.98 0.13 -0.81 -1.46 -2.14 1.99 217.29 
Carbamazepine 0 Train -9.01327 1.89 1.89 1.89 1.89 1.89 1.89 236.27 
Cefamandole 0 Train -12.5559 -0.17 -2.87 -3.55 -3.75 -3.8 -0.0443 462.5 
Chloroquine 0 Train -9.54703 0.31 0.65 1.16 1.59 3.81 4.41 319.87 
Chlorpromazine 1 Train -10.384 2.08 2.15 2.51 3.24 5.09 5.18 318.86 
Chlorprotixene 1 Train -9.43621 2.11 2.24 2.77 3.57 5.17 5.21 315.86 
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Chlorzoxazone  0 Train -7.33279 1.82 1.82 1.81 1.78 0.39 1.82 169.57 
Cholic acid f 0 Train -12.4251 2.88 2.06 1.13 0.27 -0.85 2.88 408.57 
Chrysin 1 Train -8.91189 3.13 3.07 2.73 1.92 -0.98 3.13 254.24 
Colchicine 0 Train -11.965 1.07 1.07 1.07 1.07 1.07 1.07 399.44 
Cyclosporine-A 1 Train -17.6087 2.79 2.79 2.79 2.79 2.79 2.79 1202.61 
Dehydroisoandrosterone-3-
sulfate 
0 Train -11.7764 0.022 0.022 0.022 0.022 0.022 3.52 368.49 
Desipramine  0 Train -9.75257 0.72 0.88 0.95 1.27 3.48 3.97 266.38 
Digoxin 0 Train -14.2525 1.29 1.29 1.29 1.29 1.29 1.29 780.94 
Dipyridamole 1 Train -12.3463 0.51 2.61 3.19 3.33 3.35 3.35 504.63 
Erythromycin  0 Train -13.1349 -1.19 -0.54 0.35 1.16 1.9 1.91 733.93 
Estradiol-17ß-glucuronide  0 Train -14.0062 3.72 0.99 0.3 0.0959 -0.11 3.81 448.51 
Etoposide 0 Train -15.3638 0.28 0.28 0.27 0.27 -0.058 0.28 588.56 
Felodipine  1 Train -10.0143 3.98 4.76 4.76 4.76 4.76 4.76 384.25 
Fexofenadine  0 Train -10.3285 0.64 1.21 1.23 1.23 0.65 3.73 501.66 
Flupentixol 1 Train -11.2379 -0.21 1.93 2.85 3.44 3.67 3.67 434.52 
Fumitremorgin C  0 Train -10.6711 3.34 3.34 3.34 3.34 3.34 3.34 379.45 
Gefitinib  1 Train -11.4356 -1.4 0.97 2.07 2.56 2.7 2.7 446.9 
Genistein 1 Train -9.52938 3.11 3.06 2.73 1.93 -1.39 3.11 270.24 
GF120918 1 Train -11.6435 1.33 2.21 3.14 3.9 4.43 4.43 563.64 
Glibenclamide 1 Train -11.6983 3.23 1.96 1.4 1.26 1.23 3.23 487.96 
Haloperidol 1 Train -11.1309 0.66 1.23 2.11 2.93 3.75 3.76 375.86 
Hydrochlorothiazide 0 Train -9.36376 -0.0211 -0.0213 -0.023 -0.0362 -1.52 -0.0211 297.74 
Hydrocortisone  0 Train -10.6038 1.76 1.76 1.76 1.76 1.76 1.76 362.46 
Indinavir 0 Train -12.3834 -0.65 3.06 3.38 3.43 3.43 3.44 613.79 
Indomethacin  0 Train -12.648 4.25 2.7 1.74 0.98 0.5 4.25 357.79 
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Isradipine 1 Train -10.293 3.08 3.73 3.73 3.73 3.73 3.73 371.39 
Ivermectin B 1 Train -11.5176 5.18 5.18 5.18 5.18 5.17 5.18 861.07 
Ketoconazole  1 Train -11.5704 0.59 2.66 3.51 3.93 4.04 4.04 531.43 
Kol 43 1 Train -12.4003 4.75 4.75 4.75 4.75 4.75 4.75 469.57 
Lansoprazole 0 Train -10.5519 0.41 2.57 2.58 2.58 2.27 2.58 369.36 
Loperamide 1 Train -12.6576 1.05 1.92 2.85 3.61 4.14 4.15 477.04 
Lopinavir 1 Train -12.4287 5.41 5.42 5.42 5.42 5.42 5.42 628.8 
Maprotiline  1 Train -9.88752 1.26 1.27 1.3 1.51 3.65 4.36 277.4 
Medroxyprogesterone 1 Train -11.0971 3.58 3.58 3.58 3.58 3.58 3.58 344.49 
Methotrexate  0 Train -13.238 -2.95 -3.79 -4.71 -5.1 -5.19 -0.45 454.44 
Metoprolol  0 Train -10.6079 -1.47 -1.42 -1.14 -0.47 1.5 1.63 267.36 
Mifepristone 1 Train -13.4632 3.74 5.91 6.15 6.19 6.19 6.19 429.59 
Mitoxantrone 0 Train -13.8765 -3.14 -2.52 -2.26 -1.58 -2.1 1.55 444.48 
MK571  1 Train -12.0043 3.01 2.16 1.19 0.37 -0.34 3.41 515.09 
Naringenin 0 Train -8.34123 2.63 2.62 2.56 2.23 -1.5 2.63 272.25 
Nevirapine  0 Train -7.82787 0.57 2.61 2.64 2.64 2.64 2.64 266.3 
Nicotine 0 Train -7.39101 -3.47 -2.22 -1.46 -0.62 0.55 0.57 162.23 
Nitrendipine  1 Train -10.0341 2.98 3.81 3.81 3.81 3.81 3.81 360.36 
Noscapine 1 Train -12.009 -0.69 1.51 2.17 2.35 2.38 2.38 413.42 
Omeprazole 0 Train -9.92282 -0.5 2.29 2.35 2.35 1.51 2.36 345.42 
P-aminohippuric acid 0 Train -8.22464 -0.71 -2.26 -3.17 -3.69 -3.87 -0.12 194.19 
Phenobarbital  0 Train -8.69968 0.5 -1.12 -2.58 -3.75 -3.99 0.51 232.24 
Phenylethyl isothiocyanate 0 Train -7.48819 3.47 3.47 3.47 3.47 3.47 3.47 163.24 
Phenytoin  0 Train -8.58507 1.42 1.42 1.42 1.38 -0.0121 1.42 252.27 
Pravastatin 0 Train -12.161 2.21 0.9 -0.0679 -0.88 -1.54 2.21 424.53 
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Prazosin 0 Train -11.6336 -0.36 1.09 1.83 2.08 2.14 2.14 383.4 
Probenecid 0 Train -8.61481 2.5 0.72 -0.13 -0.53 -0.64 2.51 285.36 
Procyclidine 1 Train -9.85814 0.76 0.77 0.82 1.08 3.27 3.86 287.44 
Propafenone 1 Train -11.4718 0.25 0.31 0.66 1.37 3.25 3.35 341.44 
Propranolol 0 Train -10.6551 -0.2 -0.15 0.12 0.79 2.77 2.9 259.34 
Quinidine 1 Train -9.33007 -1.27 -0.26 0.22 0.98 2.75 2.82 324.42 
Quinine  1 Train -11.5582 -1.27 -0.26 0.22 0.98 2.75 2.82 324.42 
Ranitidine  0 Train -9.9842 -3.63 -2.73 -1.91 -1.07 -0.078 -0.0681 314.4 
Reserpine 1 Train -14.4181 1.35 2.71 3.63 4.21 4.45 4.45 608.68 
Rifampicin 0 Train -15.8589 -0.89 0.0531 0.12 -0.12 -1.79 2.39 822.94 
Ritonavir 1 Train -12.8296 1.41 2.33 2.33 2.33 2.32 2.33 720.94 
Saquinavir 1 Train -13.8533 1.89 4.22 4.87 5.05 5.04 5.08 670.84 
Silymarin  1 Train -15.6766 4.23 4.22 4.13 3.73 -0.0292 4.23 482.44 
Simvastatin 1 Train -11.981 4.72 4.72 4.72 4.72 4.72 4.72 418.57 
Sotalol 0 Train -9.84715 -2.86 -2.78 -2.39 -1.68 -1.25 0.24 272.36 
Sulfasalazine 0 Train -11.5425 2.74 0.0689 -0.079 -0.0992 -0.63 3.05 398.39 
Sulfinpyrazone 0 Train -11.8182 1.82 -0.42 -0.59 -0.61 -0.61 1.89 404.48 
Sulindac 0 Train -11.1001 2.55 1.29 0.32 -0.49 -1.19 2.55 356.41 
Taurolithocholic acid  1 Train -12.8362 3.19 0.58 0.52 0.51 0.51 4.01 483.7 
Terfenadine  1 Train -11.7306 2.52 2.57 2.9 3.6 5.51 5.62 471.67 
Testosterone  0 Train -9.95339 3.18 3.18 3.18 3.18 3.18 3.18 288.42 
Tetracycline 1 Train -11.5913 -2.48 -1.91 -1.95 -2.22 -3.98 0.62 444.43 
Thioridazine 1 Train -10.7016 2.8 2.82 2.98 3.49 5.65 5.9 370.57 
Tipranavir 1 Train -14.1479 6.91 5.74 4.28 2.9 2.42 6.92 602.66 
Trimethoprim  0 Train -9.99812 -1.9 -0.8 0.0441 0.47 0.59 0.59 290.32 
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Valproic acid  0 Train -7.56993 2.58 1.81 0.89 0.0231 -1.16 2.58 144.21 
Verapamil 1 Train -12.5489 0.92 1.08 1.64 2.46 3.99 4.02 454.6 
Vinblastine 1 Train -13.5105 1.76 3.47 4.65 5.43 5.91 5.92 810.97 
Vincristine 0 Train -14.4704 1.65 3.15 4.39 5.2 5.72 5.75 824.96 
Warfarin f 0 Train -10.0581 3.13 2.09 1.14 0.33 -0.37 3.13 308.33 
1-methyl-4-phenylpyridinium 0 Validation -7.96368 -0.29 -0.29 -0.29 -0.29 -0.29 -0.29 170.23 
Antipyrine 0 Validation -7.12224 0.42 0.44 0.44 0.44 0.44 0.44 188.23 
Apigenin 1 Validation -9.70258 2.13 2.07 1.73 0.93 -2.11 2.13 270.24 
Carnitine 0 Validation -8.17413 -4.7 -4.13 -4.13 -4.13 -4.13 -4.73 162.21 
Cimetidine 0 Validation -8.44976 -2.86 -1.91 -1.05 -0.39 -0.0664 - 0.0651 252.34 
Diethylstilbestrol  1 Validation -9.58714 5.33 5.33 5.33 5.33 5.09 5.33 268.35 
Diltiazem 1 Validation -12.2815 1.63 1.85 2.52 3.36 4.7 4.73 414.52 
Doxorubicin 0 Validation -14.8735 -2.86 -2.56 -1.91 -1.47 -3.57 0.24 543.52 
Ergocristine  1 Validation -12.5819 5.14 6.79 7.66 8.1 7.68 8.24 609.71 
Flucloxacillin 0 Validation -11.2097 2.73 -0.16 -0.71 -0.84 -0.87 2.89 453.87 
Hoechst 33342 0 Validation -11.0091 -2.06 0.0772 1.55 2.44 2.76 2.96 452.55 
Imatinib 1 Validation -10.4573 -1.59 0.84 1.77 2.49 2.89 2.89 493.6 
Ivermectin A 1 Validation -13.6839 5.69 5.69 5.69 5.69 5.68 5.69 875.09 
Mesalazine 0 Validation -7.5418 -1.66 -1.88 -2.26 -2.39 -2.41 0.74 153.14 
Nicardipine 1 Validation -13.6091 1.23 3.1 4.03 4.64 4.89 4.89 479.52 
Ofloxacin 0 Validation -10.9316 -1.24 -0.16 -0.0777 -0.39 -1.84 1.86 361.37 
Prednisolone f 0 Validation -10.8012 1.63 1.63 1.63 1.63 1.63 1.63 360.44 
Prednisone f 1 Validation -10.6536 1.57 1.57 1.57 1.57 1.56 1.57 358.43 
Progesterone 0 Validation -10.3948 3.83 3.83 3.83 3.83 3.83 3.83 314.46 
Quercetin 1 Validation -9.80287 1.99 1.91 1.51 0.62 -3.3 1.99 302.24 
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Sparfloxacin 0 Validation -11.5689 -0.5 -0.00256 0.62 0.83 -0.54 2.6 392.4 
Tamoxifen f 1 Validation -11.7815 2.03 2.29 2.99 3.83 5.11 5.13 371.51 
Taurocholate 1 Validation -15.2546 -0.57 -3.18 -3.24 -3.25 -3.25 0.25 515.7 
Tinidazole 0 Validation -9.18538 -0.76 -0.29 -0.29 -0.29 -0.29 -0.29 247.27 
Zidovudine 0 Validation -8.79781 0.0522 0.0522 0.0518 0.0492 -0.52 0.0522 267.24 
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Appendix 4: Average Root Mean Square Deviation (RMSD 
RMSD – The root mean square deviation of the pose, in Å, from the original 
ligand. 
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Appendix 5: Predicted vs Observed class for validation set of SVM 3 Model 
Compound Observed Predicted Classification confusion 
matrix 
1-methyl-4-
phenylpyridinium 
0 0 TN 
Antipyrine 0 0 TN 
Apigenin 1 0 FN 
Carnitine 0 0 TN 
Cimetidine 0 0 TN 
Diethylstilbestrol  1 1 TP 
Diltiazem 1 1 TP 
Doxorubicin 0 0 TN 
Ergocristine  1 1 TP 
Flucloxacillin 0 0 TN 
Hoechst 33342 0 0 TN 
Imatinib 1 0 FN 
Ivermectin A 1 1 TP 
Mesalazine 0 0 TN 
Nicardipine 1 1 TP 
Ofloxacin 0 0 TN 
Prednisolone  0 0 TN 
Prednisone  1 0 FN 
Progesterone 0 1 FP 
Quercetin 1 0 FN 
Sparfloxacin 0 0 TN 
Tamoxifen  1 1 TP 
Taurocholate 1 0 FN 
Tinidazole 0 0 TN 
Zidovudine 0 0 TN 
 
TN – True Negative 
FN – False Negative 
TP – True Positive 
FP - False Positive 
1 – Non-substrate 
0 - Substrate 
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